[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 296757
1. Meng Y, Mauceri HJ, Khodarev NN, Darga TE, Pitroda SP, Beckett MA, Kufe DW, Weichselbaum RR: Ad.Egr-TNF and Local Ionizing Radiation Suppress Metastases by Interferon-β-Dependent Activation of Antigen-specific CD8<sup>+</sup> T Cells. Mol Ther; 2010 May;18(5):912-920

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The combination of Ad.Egr-TNF and ionizing radiation (IR) contributes to local tumor control through the production of tumor necrosis factor-α (TNFα) in the tumor microenvironment.
  • Moreover, clinical and preclinical studies with Ad.Egr-TNF/IR have suggested that this local approach suppresses the growth of distant metastatic disease; however, the mechanisms responsible for this effect remain unclear.
  • The results demonstrate that production of TNFα in the tumor microenvironment induces expression of interferon (IFNβ).
  • In turn, IFNβ stimulates the production of chemokines that recruit CD8<sup>+</sup> T cells to the tumor.
  • The results further demonstrate that activation of tumor antigen-specific CD8<sup>+</sup> CTLs contributes to local antitumor activity and suppression of DLN metastases.
  • These findings support a model in which treatment of tumors with Ad.Egr-TNF and IR is mediated by local and distant immune-mediated antitumor effects that suppress the development of metastases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 The American Society of Gene & Cell Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28178556.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Terada T: Non-functioning Well Differentiated Endocrine Carcinoma of the Pancreas. Gastroenterology Res; 2009 Dec;2(6):364-366

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-functioning Well Differentiated Endocrine Carcinoma of the Pancreas.
  • : The author reports a typical but rare case of non-functioning well differentiated endocrine carcinoma of the pancreas.
  • He has no familiar history of pancreatic neoplasms.
  • Various imaging modalities including US, CT and MRI revealed a tumor of the pancreatic body.
  • A solid well demarcated tumor was present in the pancreatic body.
  • Immunohistyochemically, tumor cells were positive for cytokeratin, synaptophysin, neuron-specific enolase, and CD56; they were negative for chromogranin, gastrin, glucagon, somatostatin, pancreatic polypeptide, and vasoactive intestinal polypeptide.
  • The pathological diagnosis was non-functioning well differentiated endocrine carcinoma of the pancreas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27990210.001).
  • [ISSN] 1918-2805
  • [Journal-full-title] Gastroenterology research
  • [ISO-abbreviation] Gastroenterology Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; Endocrine carcinoma / Histopathology / Immunohistochemistry / Pancreas
  •  go-up   go-down


3. Guan Y, Ramasamy Reddy K, Zhu Q, Li Y, Lee K, Weerasinghe P, Prchal J, Semenza GL, Jing N: G-rich Oligonucleotides Inhibit HIF-1α and HIF-2α and Block Tumor Growth. Mol Ther; 2010 Jan;18(1):188-197
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] G-rich Oligonucleotides Inhibit HIF-1α and HIF-2α and Block Tumor Growth.
  • : Hypoxia-inducible factor-1 (HIF-1) plays crucial roles in tumor promotion by upregulating its target genes, which are involved in energy metabolism, angiogenesis, cell survival, invasion, metastasis, and drug resistance.
  • The lead compounds, JG243 and JG244, which form an intramolecular parallel G-quartet structure, selectively target HIF-1α and decreased levels of both HIF-1α and HIF-2α (IC<sub>50</sub> < 2 µmol/l) and also inhibited the expression of HIF-1-regulated proteins [vascular endothelial growth factor (VEGF), Bcl-2, and Bcl-X<sub>L</sub>], but did not disrupt the expression of p300, Stat3, or p53.
  • JG243 and JG244 dramatically suppressed the growth of prostate, breast, and pancreatic tumor xenografts.
  • Western blots from tumor tissues showed that JG-ODNs significantly decreased HIF-1α and HIF-2α levels and blocked the expression of VEGF.
  • The JG-ODNs are novel anticancer agents that suppress tumor growth by inhibiting HIF-1.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 The American Society of Gene & Cell Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28178550.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Terada T: Endometriosis of the Vermiform Appendix Presenting as a Tumor. Gastroenterology Res; 2009 Dec;2(6):353-355
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometriosis of the Vermiform Appendix Presenting as a Tumor.
  • Most patients with this disease are asymptomatic or present as acute or chronic appendicitis.
  • The author herein reports a case of appendiceal endometriosis presenting as a tumor at the appendiceal oriffice.
  • A colon endoscopy showed a tumor in the appendiceal orifice.
  • Two biopsies of the tumor showed no remarkable changes.
  • Imaging modalities including CT and MRI also revealed an appendiceal tumor.
  • Resection of appendix, cecum, ascending colon, terminal ileum, and 16 lymph nodes were performed under the clinical diagnosis of gastrointestinal stromal tumor.
  • Grossly, a tumor measuring 3 x 3 x 3 cm was recognized in the appendiceral orifice.
  • Histologically, the tumor was endometriosis consisting of islands of endometrial glands and stroma.
  • The present case suggests that appendiceal endometriosis may present as a tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27990206.001).
  • [ISSN] 1918-2805
  • [Journal-full-title] Gastroenterology research
  • [ISO-abbreviation] Gastroenterology Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; Appendix / Endometriosis / Lymph nodes
  •  go-up   go-down


5. Carbone A, Cabras A, Gloghini A: HIV-associated Hodgkins lymphoma. Antiapoptotic pathways and mechanisms for immune escape by tumor cells in the setting of improved immunity. Int J Biol Markers; 2007 Apr - Jun;22(2):161-163

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-associated Hodgkins lymphoma. Antiapoptotic pathways and mechanisms for immune escape by tumor cells in the setting of improved immunity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28207144.001).
  • [ISSN] 1724-6008
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


6. Huang JH, Zhang SN, Choi KJ, Choi IK, Kim JH, Lee M, Kim H, Yun CO: Therapeutic and Tumor-specific Immunity Induced by Combination of Dendritic Cells and Oncolytic Adenovirus Expressing IL-12 and 4-1BBL. Mol Ther; 2010 Feb;18(2):264-274
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic and Tumor-specific Immunity Induced by Combination of Dendritic Cells and Oncolytic Adenovirus Expressing IL-12 and 4-1BBL.
  • : Recently, gene-based cytokine treatment has been actively pursued as a new promising approach in treating cancer.
  • Moreover, enhanced type-1 antitumor immune response and higher migratory abilities of DCs in tumors were also observed in the combination arms.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 The American Society of Gene & Cell Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28182938.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Bal A, Mohan H, Chabbra S, Sood S: Causes of enucleation in Northern India (1995-2005). Eur J Ophthalmol; 2007 Jul-Aug;17:638-641

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Between January 1995 and June 2005, there were 139,092 outpatients, 6,574 hospital admissions, 12,044 ophthalmic operations, and a total of 48 enucleations in 47 patients.
  • On histopathologic examination, the lesions were categorized into two broad groups: neoplastic (8 cases, 16.6%) and non-neoplastic (40 cases, 83.4%).
  • CONCLUSIONS: In our setting, non-neoplastic lesions are the main cause of eyeball surgery, as compared to the West, where trauma followed by neoplasms constitute important causes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28221561.001).
  • [ISSN] 1724-6016
  • [Journal-full-title] European journal of ophthalmology
  • [ISO-abbreviation] Eur J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


8. Ulusan S, Koc Z, Kayaselcuk F: Spontaneously Ruptured Gastrointestinal Stromal Tumor With Pelvic Abscess: A Case Report and Review. Gastroenterology Res; 2009 Dec;2(6):361-363

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneously Ruptured Gastrointestinal Stromal Tumor With Pelvic Abscess: A Case Report and Review.
  • : Gastrointestinal stromal tumors (GISTs) originate from interstitial Cajal cells on intestinal pacemaker cells that arise from the muscularis propria of the gastrointestinal tract wall.
  • GISTs are characterized by the expression of c-KIT protein (CD 117, stem cell factor receptor) and are the most common mesenchymal tumors of the digestive tract.
  • The rupture of a gastrointestinal stromal tumor of the peritoneal cavity is critical complication, although it is infrequently described in the literature.
  • We describe the computed tomographic findings of a ruptured gastrointestinal stromal tumor of the jejunal wall with an accompanying abscess.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27990209.001).
  • [ISSN] 1918-2805
  • [Journal-full-title] Gastroenterology research
  • [ISO-abbreviation] Gastroenterology Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; Abdominal abscess / Gastrointestinal stromal tumors / X-Ray computed tomography
  •  go-up   go-down


9. Fijolek J, Wiatr E, Rowinska-Zakrzewska E, Giedronowicz D, Langfort R, Chabowski M, Orlowski T, Roszkowski K: p53 and HER2/neu expression in relation to chemotherapy response in patients with non-small cell lung cancer. Int J Biol Markers; 2006 Apr-Jun;21(2):81-87
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p53 and HER2/neu expression in relation to chemotherapy response in patients with non-small cell lung cancer.
  • : The aim of the study was to investigate a relation between p53 and HER2/neu expression in resected lung tumors and the response of those tumors to neoadjuvant chemotherapy.
  • The study population included 67 consecutive patients with non-small cell lung cancer (NSCLC) in stage II or III who were operated on at the Institute of Tuberculosis, Warsaw, Poland, between 20 April 2001 and 10 March 2003.
  • The response to therapy was assessed as complete response (CR), partial response (PR), stable disease (SD) or progressive disease (PD), on the basis of CT scans performed before and after neoadjuvant chemotherapy. p53 and HER2/neu protein expression were evaluated by immunohistochemistry (IHC) using antibodies against p53 (clone PAb 1801, Novocastra) and against HER2/neu (Dako) in paraffin-embedded specimens of tumors.
  • A response to therapy (CR+PR) was observed in 27 patients, while 40 patients (SD+PD) were regarded as resistant to therapy.
  • Resistance was observed significantly more often in tumors above 3 cm in diameter. p53 expression was found in 16 tumors (23.9%) and HER2/neu in 26 tumors (38.8%).
  • We observed a nonsignificant tendency to chemoresistance in tumors with HER-2/neu overexpression and also in tumors with p53 overexpression.
  • This significance was independent of tumor size.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28207130.001).
  • [ISSN] 1724-6008
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


10. Rosa MA, Maccauro G, Muratori F, Roda' MG: Endoprosthetic replacement for malignant bone tumours of the proximal femur. Hip Int; 2005 Oct - Dec;15(4):218-222

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoprosthetic replacement for malignant bone tumours of the proximal femur.
  • : Limb salvage procedures are considered the gold standard in the treatment of bone tumours.
  • The use of modular prostheses is one of the options for reconstruction after bone resection in primary tumours and in very restricted cases also in bone metastases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28224591.001).
  • [ISSN] 1724-6067
  • [Journal-full-title] Hip international : the journal of clinical and experimental research on hip pathology and therapy
  • [ISO-abbreviation] Hip Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


11. Song CK, Han HD, Noh KH, Kang TH, Park YS, Kim JH, Park ES, Shin BC, Kim TW: Chemotherapy Enhances CD8&lt;sup&gt;+&lt;/sup&gt; T Cell-mediated Antitumor Immunity Induced by Vaccination With Vaccinia Virus. Mol Ther; 2007 Aug;15(8):1558-1563

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : The use of immunotherapy or chemotherapy alone is generally ineffective against well-established tumors.
  • To overcome this intrinsic resistance against therapy for tumors, we have attempted to combine immunotherapy with chemotherapy.
  • In this study, we tried to induce a rapid antitumor effect via chemoimmunotherapy using a vaccinia viral vaccine as an immunotherapeutic agent with anticancer agents including epigallocatechin-3-gallate (EGCG) and conventional anticancer drugs.
  • Although a combination of vaccinia-mediated vaccination and chemotherapy led to a strong inhibition of tumor growth, monotherapy alone failed to completely cure tumors.
  • In contrast, intravenous injection of cisplatin (CDDP) or cyclophosphamide (CTX) after vaccinia virus vaccination led to complete regression of the established tumors.
  • This effect is mainly associated with the enhanced tumor-specific CD8<sup>+</sup> T cell immune response induced by vaccinia virus, which was demonstrated by antibody depletion.
  • However, anticancer drugs alone failed to induce a significant enhancement of the tumor-specific CD8<sup>+</sup> T cell immune response.
  • Taken together, these results suggest that combining vaccinia virus-based immunotherapy with anticancer drugs is particularly effective against established tumors by increasing the tumor antigen-specific CD8<sup>+</sup> T cell immune response, which is primed by vaccinia virus-mediated vaccination.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2007 The American Society of Gene Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28182877.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Akbulut H, Coleri A, Acikgoz N, Sahin G, Ozkal P, Tang Y, Icli F, Deisseroth A: Effect of GM-CSF on tumor-specific immune response and antitumoral efficacy when combined with suicide gene therapy. J Clin Oncol; 2009 May 20;27(15_suppl):e14610

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of GM-CSF on tumor-specific immune response and antitumoral efficacy when combined with suicide gene therapy.
  • Combination of an immunotherapy modality with suicide gene therapy would increase the tumor eradciating efficacy of either treatment strategy used alone.
  • We tested the in vitro efficacy of the vectors in both human and mouse tumor cell lines and in a syngeneic mouse model of colon cancer with tumor explants of CRL 2638 cells.
  • RESULTS: Our results show that the vectors carrying CD/GM-CSF transcription units are effective in terms of killing of tumor cells when 5-FC added.
  • In the syngeneic colon cancer model, addition of GM-CSF significantly increased tumor-specific cellular immune response when compared to suicide gene therapy alone. (p<0.01).
  • Likewise, GM-CSF addition caused a 8 times reduction in the ratio of Tregs infiltrating the tumor nodules (p<0.001).
  • Accordingly, GM-CSF decreased the tumor growth by 2 times an d increased the median survival time by 50% (p<0.01).
  • CONCLUSIONS: These impressive results of in-vitro cytotoxicity and encouraging results of in-vivo testing of the our newly constructed GM-CSF carrying vector suggest a potential for the use of the vector for the treament of established tumors by inducing tumor specific immune response.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964114.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Lassman AB, Oligodendroglioma Study Group: Retrospective analysis of outcomes among more than 1,000 patients with newly diagnosed anaplastic oligodendroglial tumors. J Clin Oncol; 2009 May 20;27(15_suppl):2014

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective analysis of outcomes among more than 1,000 patients with newly diagnosed anaplastic oligodendroglial tumors.
  • : 2014 Background: Treatment of anaplastic oligodendroglial tumors is controversial.
  • 1p19q co-deletion was observed in 292 (48%) and no deletion in 232 (38%) of 606 tested tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964586.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Alabi S, Rahman G, Badmos K: Pattern of head and neck cancers in a Nigerian tertiary health center: A 10-year review. J Clin Oncol; 2009 May 20;27(15_suppl):e17054

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A variety of different tumour types may arise at a host of sites within the head and neck region.
  • Information extracted from the case notes of patients with histological results included: Age, sex, clinical features, site of tumour, and the histological types of tumour.
  • The International classification of disease oncology (ICDO) ninth version was used to categorize the sites of the tumour.
  • The devastating effects on the individual, family and the community are enormous in a setting with late presentations at the hospital and a strong belief in traditional medicine.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961823.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Duff JM, Leather HL, Walden EO, LaPlant KD, George TJ Jr: Adequacy of published oncology randomized controlled trials to provide details needed for clinical application. J Clin Oncol; 2009 May 20;27(15_suppl):6536

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adequacy of published oncology randomized controlled trials to provide details needed for clinical application.
  • Although manuscript submissions follow a standard scientific format, major oncology journals have minimal standards for reporting treatment administration.
  • METHODS: All therapy-based phase III oncology RCTs published between 2005-2008 in the Journal of Clinical Oncology (JCO), The New England Journal of Medicine (NEJM), Journal of the National Cancer Institute (JNCI), Blood, and Cancer were eligible for inclusion.
  • Physicians and oncology pharmacists were surveyed for details needed for clinical practice.
  • Premedications, growth factor support, and dose adjustments for hematologic or organ toxicity were reported less than half the time (p<0.0001).
  • CONCLUSIONS: RCTs published in top tier oncology journals fail to consistently report full details needed for clinical application.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964046.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Litterman AJ, Yancovitz M, Shapiro R, Berman R, Pavlick A, Daarvishian F, Blank S, Lee P, Osman I, Polsky D: Detection of BRAF kinase mutations in melanoma, ovarian, and prostate carcinomas: Evidence for tumor heterogeneity in clinical samples. J Clin Oncol; 2009 May 20;27(15_suppl):11031

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of BRAF kinase mutations in melanoma, ovarian, and prostate carcinomas: Evidence for tumor heterogeneity in clinical samples.
  • : 11031 Background: Several studies have provided evidence that solid tumors are polyclonal malignancies, an observation which may contribute to difficulties in achieving durable treatment responses.
  • In some patients, molecularly targeted therapies may be compromised due to heterogeneity among tumor subclones.
  • In this study we compared conventional DNA sequencing with a fluorescent-based mutant-specific PCR (MS-PCR) assay to detect the BRAF hotspot mutation V600E in a large panel of patient tumors, including paired primary and metastatic tumors from individual patients.
  • METHODS: BRAF MS-PCR and conventional sequencing were performed on DNA from 304 tumors (112 melanoma, 110 ovarian, 82 prostate) to determine the presence of the BRAFV600E hot-spot mutation.
  • RESULTS: DNA sequencing detected mutations in 5/110 (4.5%) ovarian tumors, 1/82 (1.2%) prostate tumors, and 36/112 (32%) melanomas.
  • In contrast, the MS-PCR assay detected mutations in 12/110 (11%) ovarian tumors, 15/82 (18%) prostate tumors and 85/112 (76%) melanomas.
  • Among 18 patients with matched primary and metastatic melanoma, 8/18 (44%) had discordant results including 2 patients with mutant primary tumors and wild-type metastases; among the 19 patients with multiple metastases 5/19 (26%) had discordant (both wild-type and mutant) tumors.
  • CONCLUSIONS: Using a highly sensitive BRAF mutation detection method, we observed substantial evidence for heterogeneity within clinical tumor specimens.
  • These results suggest that failures of molecularly targeted therapies, such as those directed against mutant BRAF, may be due in part to a lack of clonality among the tumors under treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964001.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Tournigand C, Samson B, Scheithauer W, Louvet C, Andre T, Lledo G, Latreille J, Viret F, Chibaudel B, de Gramont A: mFOLFOX-bevacizumab or XELOX-bevacizumab then bevacizumab (B) alone or with erlotinib (E) in first-line treatment of patients with metastatic colorectal cancer (mCRC): Interim safety analysis of DREAM study. J Clin Oncol; 2009 May 20;27(15_suppl):4077

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To date, 117 pts with a disease control after 6 cy have had a 2<sup>nd</sup> randomisation (M): B alone (7.5 mg/kg q3w, n=56) or B+E 150 mg/d (n=61) until PD.
  • RESULTS: Pts characteristics were: sex: 124M/76F, median age: 62.4 years (26-80), primary tumors: colon 152, rectum 53, synchronous metastases: 150 pts, > 1 metastase site: 115, PS 0/1: 134/66, Alk. Ph.
  • For I, 92 pts in mFOLFOX-B and 93 in XELOX-B were evaluable for toxicity (tox).
  • For M, 56 pts in B and 61 pts in B+E were evaluable.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961633.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Buess M, Rajski M, Vogel B, Herrmann R, Rochlitz C: Tumor endothelial interaction, CD44+/CD24- stem cell signature, and prognosis in early-stage breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):503

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor endothelial interaction, CD44+/CD24- stem cell signature, and prognosis in early-stage breast cancer.
  • : 503 Background: The effects of tumor-endothelial interaction on global gene expression in breast cancer are not yet well characterized.
  • We hypothesized that gene expression signatures induced by tumor-endothelial interaction might be of clinical relevance.
  • METHODS: To this aim we set up an ex vivo co-culture model with human benign and a panel of 6 malignant breast epithelial cells in combination with human venous and microvascular endothelial cells and determined associated gene expression changes with cDNA microarrays.
  • While in monoculture tumor cells containing the stem cell like CD44+/CD24- signature showed a lower expression of the "M-phase cell cycle" genes than the CD44-/CD24+ cells, in the co-cultures with CD44+/CD24- cells these genes were induced.
  • Interestingly, these tumor cells co- expressed a set of angiogenic factors such as VEGF, PTN, and FGF12 mRNA at significantly higher levels.
  • In vivo, the expression of the gene set derived from the co-culture was remarkably coherent providing a basis for segregation of tumors into two groups.
  • In a univariate analysis, early stage tumors with high expression levels (n= 137) of "M-phase cell cycle" genes had a significantly lower distant metastasis-free survival (p=1.8e-5) (50 % at 10 years) and overall survival rate (p= 5e-9) (52 % at 10 years) than tumors with low expression levels (n= 158) (metastasis-free survival: 73 %; overall survival: 84 % at 10 years).
  • CONCLUSIONS: Our results suggest that the interaction of tumor cells expressing the CD44+/CD24- stem cell like signature, implicating a low proliferative potential, with endothelial cells might explain the unexpected and paradoxical association of the CD44+/CD24- signature with highly proliferative tumors with an unfavorable prognosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960783.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Lunsford LD, Niranjan A, Flickinger JC, Maitz A, Kondziolka D: Radiosurgery of vestibular schwannomas: summary of experience in 829 cases. J Neurosurg; 2005 Jan;102(s_supplement):195-199

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Optimal outcomes reflect long-term tumor control, preservation of cranial nerve function, and retention of quality of life.
  • The average tumor volume was 2.5 cm<sup>3</sup>.
  • The median margin dose to the tumor was 13 Gy (range 10-20 Gy).
  • Unchanged hearing preservation was possible in 50 to 77% of patients (up to 90% in those with intracanalicular tumors).
  • Trigeminal symptoms were detected in less than 3% of patients whose tumors reached the level of the trigeminal nerve.
  • Tumor control rates at 10 years were 97% (no additional treatment needed).
  • CONCLUSIONS: Superior imaging, multiple isocenter volumetric conformal dose planning, and optimal precision and dose delivery contributed to the long-term success of GKS, including in those patients in whom initial microsurgery had failed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28306432.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; gamma knife surgery / radiosurgery / vestibular schwannoma
  •  go-up   go-down


20. Dong M, Ning Z, Newman MJ, Xu J, Dou G, Cao H, Shi Y, Gingras MA, Lu X, Feng F: Phase I study of chidamide (CS055/HBI-8000), a novel histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas. J Clin Oncol; 2009 May 20;27(15_suppl):3529

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of chidamide (CS055/HBI-8000), a novel histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas.
  • : 3529 Background: Chidamide (CS055/HBI-8000) is a new benzamide type of histone deacetylase (HDAC) inhibitor with low nanomolar activity against HDAC1, 2, 3 and 10.
  • This Phase I study evaluated the safety and tolerability of chidamide in patients (pts) with advanced solid tumors and lymphomas.
  • METHODS: 31 pts with refractory or relapsed advanced solid tumors (22) and lymphomas (9) were enrolled in this study.
  • Single dose PK analysis in pts with 25, 32.5 and 50 mg revealed T1/2 of 16.8-18.3 h, Tmax of 1-2 h in most cases, and a dose-related increase in Cmax and AUC.
  • 4 pts with T-cell lymphomas (4/5 evaluable) and 1 pt with submandibular adenoid cystic carcinoma achieved PR, and 11 pts (2 B-cell lymphomas and 9 solid tumors) experienced SD.
  • CONCLUSIONS: Chidamide was well-tolerated in pts with advanced solid tumors and lymphomas in the tested regimens.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961317.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Capdevila J, Clive S, Tabernero J, Lardelli P, Soto-Matos A, Baselga J, Piera A, Pardos I, Rye R, Smyth JF: Phase I study of the novel anticancer drug PM00104 as a 24-hour IV infusion every 3 weeks (q3w) in patients (pts) with advanced solid tumors or lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):2568

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of the novel anticancer drug PM00104 as a 24-hour IV infusion every 3 weeks (q3w) in patients (pts) with advanced solid tumors or lymphoma.
  • PM00104 has shown broad in vitro and in vivo anti-tumor activity (IC<sub>50</sub> ≤ 10<sup>-8</sup> M) with an acceptable toxicology profile.
  • METHODS: The aim of this phase I study was to assess the safety profile, dose-limiting toxicities (DLT), maximum tolerated dose (MTD), recommended dose (RD), pharmacokinetics (PK), relationship between PK and pharmacodynamics (PD) and anti-tumor activity of PM00104 administered as a 24-hour i.v. infusion q3w.
  • Sequential cohorts of 3-6 pts were treated at 133, 266, 400, 800, 900, 1600, 3200, 4000 and 5000 μg/m<sup>2</sup>.
  • Five pts developed DLTs: 2 pts at 5000 μg/m<sup>2</sup> (grade 4 thrombocytopenia/neutropenia and grade 3 nausea/vomiting in 1 pt; and grade 3 nausea in 1 pt); 1 at 4000 μg/m<sup>2</sup> (grade 4 neutropenia/thrombocytopenia and grade 3 asthenia); 1 at 3200 μg/m<sup>2</sup> (grade 3 tumor pain) and 1 at 266 μg/m<sup>2</sup> (grade 3 transaminase increase).
  • At the RD 6 more pts have been included in order to further evaluate the safety profile and anti-tumor activity.
  • Other adverse events included nausea and vomiting (more frequent at doses ≥800 μg/m<sup>2</sup>), fatigue, anorexia and diarrhea; most of them being of ≤grade 2 severity.
  • No objective responses were seen but 3 pts with pancreatic adenocarcinoma, hepatocarcinoma and lower esophagus adenocarcinoma presented stable disease lasting >3 months.
  • CONCLUSIONS: PM00104 has shown an acceptable safety profile with signs of anti-tumor activity in pts with advanced malignancies when administered as a 24-hour i.v. infusion q3w.
  • PM00104 is also being evaluated with other administration schedules as monotherapy and in combination with other anti-tumor agents.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961881.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA008748
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Gutierrez M, Murgo AJ, Allen D, Turkbey I, Gardner ER, Trepel J, Chen H, Giaccone G, Doroshow JH, Kummar S: Phase I study of vandetanib (V) and bevacizumab (B) combination therapy evaluating the VEGF and EGF signal transduction pathways in adults with solid tumors and NHL. J Clin Oncol; 2009 May 20;27(15_suppl):3522

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of vandetanib (V) and bevacizumab (B) combination therapy evaluating the VEGF and EGF signal transduction pathways in adults with solid tumors and NHL.
  • OBJECTIVES: Determine the toxicity profile and the MTD of the combination of (V+B); evaluate (V) pharmacokinetics, changes in tumor vascularity by dynamic contrast enhanced MRI (DCE-MRI) and effects of (V+B) treatment on circulating endothelial progenitors and mature circulating endothelial cells.
  • Other gr 2-3 toxicities seen beyond 2 cycles included: diarrhea, elevated creatinine, leucopenia, anemia, thrombocytopenia, hemorrhage, prolonged QTc interval, proteinuria, rash (hand-foot syndrome / acneiform).
  • Partial Response (PR) was achieved in 2 pts (pancreatic 14 mos + and JAC 6 mos); disease stabilization in 5 pts (4 mos +).
  • DCE-MRI results showed a reduction in the parameters of permeability, (ktrans and kep), associated with one PR.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961325.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Mack PC, Holland WS, Redman M, Lara PN Jr, Snyder LJ, Hirsch FR, Franklin WA, Kim ES, Herbst RS, Gandara DR: KRAS mutation analysis in cetuximab-treated advanced stage non-small cell lung cancer (NSCLC): SWOG experience with S0342 and S0536. J Clin Oncol; 2009 May 20;27(15_suppl):8022

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KRAS mutation analysis in cetuximab-treated advanced stage non-small cell lung cancer (NSCLC): SWOG experience with S0342 and S0536.
  • In colorectal cancer, benefit from the EGFR-targeted monoclonal antibody cetuximab is largely limited to patients (pts) whose tumors are KRAS wild-type (WT).
  • METHODS: DNA extracted from archival tumor and plasma specimens from S0342 (carboplatin-paclitaxel plus sequential vs. concurrent cetuximab) and S0536 (carboplatin-paclitaxel-cetuximab-bevacizumab) was analyzed for KRAS mutations by micro-dissection/sequencing and/or Scorpion-ARMS (DxS LTD).
  • No differences between mutant and WT tumors were observed for response rate (p=0.62) or progression-free survival (PFS; p=0.65).
  • Overall survival (OS) was non-significantly higher for pts with WT vs. mutant KRAS [median OS: 11 vs. 8 mo. ; p=0.39].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962804.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Gualberto A, Dolled-Filhart MP, Hixon ML, Christensen J, Rimm DL, Lee AV, Wang Y, Pollak M, Paz-Ares LG, Karp DD: Molecular bases for sensitivity to figitumumab (CP-751,871) in NSCLC. J Clin Oncol; 2009 May 20;27(15_suppl):8091

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 8091 Background: Signaling of Insulin like Growth Factors (IGFs) through the IGF type 1 receptor (IGF-IR) induces tumor resistance to cancer therapy.
  • Figitumumab (F) (CP-751,871), a specific IGF-IR inhibitor, has shown phase 2 activity in NSCLC in some histologies (i.e., squamous cell and adenocarcinoma) but not others (i.e, large cell or NOS tumors).
  • METHODS: Protein expression of members of the IGF-IR pathway, EGFR and differentiation markers was determined in core biopsies from 230 NSCLC pts, including 52 pts enrolled in F trials.
  • This subset included 73% of the squamous cell tumors investigated (N=44).
  • Large cell/NOS NSCLC expressed the highest levels of vimentin (p<0.001) but had low E-cadherin and IGF-IR expression and low fIGF-1 plasma levels.
  • Analysis of anchorage independent growth in NSCLC cell lines confirmed that F activity is independently associated to IGF-IR overexpression (p=0.02) and IGFBP3 under-expression (p=0.009).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962669.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Samlowski WE, Moon J, Tuthill RJ, Heinrich MC, Balzer-Haas NS, Merl SA, DeConti RC, Thompson JA, Flaherty LE, Sondak VK: A phase II trial of imatinib mesylate in Merkel cell carcinoma (neuroendocrine carcinoma of the skin): A Southwest Oncology Group Study (S0331). J Clin Oncol; 2009 May 20;27(15_suppl):9056

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of imatinib mesylate in Merkel cell carcinoma (neuroendocrine carcinoma of the skin): A Southwest Oncology Group Study (S0331).
  • RESULTS: A total of 25 patients were accrued to this trial from 13 institutions, with 6 accrued through Intergroup participation by the Eastern Cooperative Oncology Group.
  • Two patients were ineligible (one was found not to express CD117 on central pathology review, and one lacked measurable disease).
  • In addition, stable disease was observed in 3 patients (9, 4 and 3 months).
  • All were attributed to tumor progression.
  • One patient achieved a partial response and another had prolonged disease stabilization while receiving treatment.
  • DNA sequencing of c-KIT was performed on tumor tissue from on a non- responding patient and the one patient with long-term stable disease (9 months).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962132.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Soni M, Saha S, Korant A, Chakravarty B, Arora S, Iddings D, Sirop S, Bisnoi R, Wiese D, Singh T: Correlation of bone marrow micrometastasis to TNM stage of colorectal tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e15039

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of bone marrow micrometastasis to TNM stage of colorectal tumors.
  • Prior to resection of the primary tumor, pts underwent bilateral posterior-superior-iliac spine BM aspiration and samples were examined for presence of micrometastasis by Automated Cellular Imaging System using Chroma Vision Cytokeratin Detection Kit to detect cells expressing CK 8 as defined by CAM 5.2 monoclonal antibody.
  • Of 113 total Colon pts, 27%(31/113) had nodal disease without distant metastasis(stage III); 13%(4/31) of these pts had BMM with 60% (3/5) unilaterally and 40%(2/5) bilaterally.
  • In the Rectal group, 16%(7/42) had stage 3 disease; 14% (1/7) of stage 3 rectal pts had BMM.
  • CONCLUSIONS: BMM did not correlate with tumor size, nodal status or distant metastasis.
  • This discrepancy between tumor stage and BMM suggests BMM to operate independently of TNM staging.
  • Further studies correlating prognosis and disease free survival in +ve BMM pts are needed to examine the significance of BMM in CrCa.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964467.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Bredel M, Renfrow J, Yadav A, Alvarez A, Lin D, Scholtens D, He X, Chandler J, Scheck A, Harsh G: Role of IκBα as a negative regulator of EGFR and a molecular determinant of prognosis in glioblastoma multiforme. J Clin Oncol; 2009 May 20;27(15_suppl):2028

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of IκBα as a negative regulator of EGFR and a molecular determinant of prognosis in glioblastoma multiforme.
  • : 2028 Background: Glioblastoma multiforme is a complex disease that involves the deregulation of overlapping signaling pathways.
  • Constitutive activation of the transcription factor nuclear factor-κB (NF-κB) has been broadly associated with various human cancers, including glioblastomas, and their therapy resistance and may be due to cross-coupling with other oncogenic pathways, such as epidermal growth factor signaling.
  • Functional analyses uncover a bona fide tumor suppressor role for IκBα in glioblastoma cells, where it functions to constrain tumorigenic and migratory potential, and induce spontaneous cellular senescence, and apoptosis in response to treatment.
  • Glioblastomas with initially high IκBα expression significantly repress IκBα upon tumor recurrence, suggesting an acquired mechanism to evade its tumor-suppressive and/or chemo-sensitizing effects during tumor progression.
  • CONCLUSIONS: IκBα is a molecular determinant of biological tumor behavior and patient survival in glioblastoma multiforme.
  • Deletion of NFKBIA could present an alternate mechanism to activate EGFR signaling in EGFR non-amplified glioblastomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964596.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Harris TJ, Jones DR, Brenin CM, Kelly KA, George K, Moskaluk CA: Evaluation of plectin-1 immunohistochemical staining in human non-small cell lung cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e22118

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of plectin-1 immunohistochemical staining in human non-small cell lung cancer.
  • : e22118 Background: Plectin-1 (PLEC1), a known scaffolding protein, impacts signaling pathways and has been found to be up-regulated and redistributed to the cell membrane in tumor cells.
  • The purpose of this study was to examine the variation of PLEC1 staining in human non-small cell lung cancer (NSCLC).
  • A total PLEC1 immunohistochemical (IHC) staining score was obtained by multiplying the intensity of PLEC1 staining, scored 0 through 3, by the percent of tumor cells showing membrane staining, scored 1 for <25%, 2 for 25%-75% and 3 for >75%.
  • The samples were then grouped into low (0-2), intermediate (3-5) or high (6- 9) membrane expression and analyzed for clinical correlations to tumor type and pathological staging.
  • There was a trend of lower PLEC1 staining as the tumor stage advanced (p=0.1).
  • As this biomarker is being developed for molecular imaging modalities in other tumor types, it may have potential to be of use in the non-invasive detection of disease or therapeutic efficacy monitoring in NSCLC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963515.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Presant CA, Bosserman L, Howard F, Emilio B: Patterns of metastatic (met) disease sites in breast cancer (BrCa): Implications for availability of fresh tumor tissue (FTT) for personalized BrCa treatment (Rx) planning (TP) in met disease. J Clin Oncol; 2009 May 20;27(15_suppl):e12004

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of metastatic (met) disease sites in breast cancer (BrCa): Implications for availability of fresh tumor tissue (FTT) for personalized BrCa treatment (Rx) planning (TP) in met disease.
  • Although archival tissue is available in all PTs, FTT testing of molecular, immunohistochemical, and/or chemosensitivity characteristics may be more optimal for TP than tissues obtained before previous Rx and/or new mets, and archival tissue is inadequate for cell culture information.
  • In order to theoretically obtain FTT for development of a personalized TP based on an algorithm preferring in order local bx > para/thoracentesis, > non-osseous needle bx > video-assisted tissue bx > osseous bx, 18% of PTs would have had a local bx, 3% para/thoracentesis, 23% liver bx, 19% lung bx, 17% bone bx, and 12% would not have had a bx because of brain-only mets.
  • CONCLUSIONS: Most BrCa PTs in oncology practices have only locoregional disease.
  • FTT acquisition would be feasible for 88% of PTs with mets for personalized TP, and in most the bx would be simple and non-invasive.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964266.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Khattab TM, Jastaniah WA, Felimban SK, Elemam N, Abdullah K, Ahmed B: How could improvement in the management of T-cell acute lymphoblastic leukemia be achieved? Experience of Princess Nourah Oncology Center, National Guard Hospital, Jeddah, Saudi Arabia. J Clin Oncol; 2009 May 20;27(15_suppl):10048

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How could improvement in the management of T-cell acute lymphoblastic leukemia be achieved? Experience of Princess Nourah Oncology Center, National Guard Hospital, Jeddah, Saudi Arabia.
  • METHODS: Retrospective review of all patients files diagnosed with T-ALL from 1989 until now with data collection including; sex, age, white cell count (WBCs), CNS disease, type of protocol used, length of survival, overall survival, cause of death (toxic, disease).
  • Overall survival 27/52 (52%) and 25 pts. died (48%); 15 secondary to disease recurrence (9 on UKALL, 4 BFM, 2 CCG 1961); 4 during induction, 1 fulminant hepatic failure, 1 tumor lysis syndrome, and 4 due to toxicities (mucormycosis, staphylococcal toxic shock syndrome, CMV pneumonia, pseudomonas sepsis).
  • Mean length of survivors 4 year (range 4-140 month) and mean length for non-survivors 1 year (range 0.1-40 months).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962474.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Fiebrich H, Brouwers AH, Kerstens MN, Pijl ME, Kema IP, de Jong JR, van der Wal JE, Sluiter WJ, de Vries EG, Links TP: Sensitivity of 6-[F-18]fluoro-L-dihydroxyphenylalanine positron emission tomography for localizing tumors causing catecholamine excess. J Clin Oncol; 2009 May 20;27(15_suppl):11064

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sensitivity of 6-[F-18]fluoro-L-dihydroxyphenylalanine positron emission tomography for localizing tumors causing catecholamine excess.
  • : 11064 Background: Positron emission tomography (PET) using the catecholamine precursor 6-[F-18]fluoro-L-dihydroxyphenylalanine (<sup>18</sup>F-DOPA) has emerged as promising technique to localize tumors with catecholamine excess.
  • <sup>18</sup>F-DOPA PET, <sup>123</sup>I-MIBG, and CT/MRI were compared using a composite reference standard derived from all available imaging, clinical and histological information.
  • The tumor localization was found in 45 patients, 43 with <sup>18</sup>F-DOPA PET, 31 with <sup>123</sup>I-MIBG and 32 with CT/MRI, resulting with surgery in final diagnosis of pheochromocytoma in 40, adrenal hyperplasia in 2, paraganglioma in 2, ganglioneuroma in 1 and 3 unknown (as yet no lesion detected).
  • CONCLUSIONS: The sensitivity of <sup>18</sup>F-DOPA PET to localize tumors with catecholamine excess is superior to either <sup>123</sup>I-MIBG scintigraphy or CT/MRI.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963142.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Koumoundourou DS Sr, Kassimatis TI, Tzorakoleftherakis E: Evaluation of Smad2/3 and Smad4 as inhibitors of estrogens and Ski protein as a predictive factor in T1, T2 N0 breast carcinomas. J Clin Oncol; 2009 May 20;27(15_suppl):1543

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of our study was to investigate the activation of Smad2/3, Smad4, and Ski proteins in breast carcinomas and correlate their expression with each other and with hormonal receptors, as well as with other clinicopathological parameters such as the tumor size and grade, and the Distant Disease Free and the Overall Survival.
  • ER and PR status, as well as the expression of Smad2/3, Smad4, and Ski proteins were evaluated using immunohistochemistry.
  • Staining of 5% of the tumor cells was adopted as a threshold.
  • RESULTS: Smad2/3 and Smad4 were strongly correlated with each other (p < 0,001) and inversely correlated with patients' DDFS (Kaplan-Meier plots, p = 0,004 for Smad2/3 and p = 0,026 for Smad4) and OS (Kaplan-Meier plots, p = 0,034 for Smad2/3 and p = 0,017 for Smad4).
  • Smad2/3 was proved to be an independent prognostic factor in grade 1 tumors, while Smad4 was inversely correlated with PR expression (p = 0,028) and had a strong prognostic value in ER+ tumors (p = 0,02).
  • Ski protein had a strong association with tumor grade (p < 0.001) and was found to be an independent prognostic factor in Cox regression analysis (p = 0,006, exp(B) = 4,98).
  • CONCLUSIONS: Smad 2/3 and Smad 4 not only are tumor suppressor molecules, but also inhibit ER dependent gene expression.
  • This inhibition is lost when Smad's expression is reduced, and that is a potent explanation for Smad 4 prognostic value in ER positive tumors.
  • Moreover the correlation with PR expression, may be due to the fact that PR is an indicator of ER pathway's integrity and also to PR's enallaktiki activation by ER-β.
  • From the other hand, Ski protein acts as an oncogene in breast carcinogenesis and contributes to the development of a more aggressive tumor phenotype.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964080.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Panopoulos CG, Tzavara C, Papadimitriou K, Pistalmatzian N, Lypas G, Barbounis V, Demiri S, Koumakis G, Apostolikas N, Efremidis A: Relationship between lymphovascular invasion (LVI) and prognostic markers in different subtypes of breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e22109

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient's age, menopausal status, tumor histology, tumor size, histologic grade, lymph node (LN) involvement, hormone receptor (HR) status and HER-2 status were determined as markers of prognosis.
  • Patients with one or more than three nodes involved had 3.95 (95% CI: 2.13-7.33) and 6.29 (95% CI: 3.14-12.63) times greater odds for LVI respectively compared with node negative tumors.
  • Age, menopausal status, tumor histology, tumor size and HR status were not significantly associated with LVI.
  • More aggressive tumors as HER-2 + tumors have a significantly higher probability of LVI, which may be used as an indicator of more aggressive behavior of the primary tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963506.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Silva J, Martinez-Velasco A: Correlating MRI, mammogram, and ultrasonography( USG): Which study most accurately predicts breast cancer size? J Clin Oncol; 2009 May 20;27(15_suppl):e11549

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e11549 Purpose: Assessment of tumor size in patients with breast cancer is based on radiologic assessment when pathology measurements are equivocal and it is also considered when neoadjuvant therapy is used.
  • Tumor size is measured as the largest dimension or for multifocal disease, as the largest dimension of the largest focus.
  • The purpose of this study was to compare the currently used imaging methods for determining breast tumors' size.
  • All women had preoperative MRI, USG and mammographic assessment of tumor size.
  • Measurements were compared to the pathologic tumor size of the surgical specimen.
  • RESULTS: The greatest tumor diameter measured was within 3 mm of the pathologic tumor size in 43.4% of patients measured by MRI, 32.6% of patients measured by USG, and 36.9% of patients measured by mammogram.
  • In average, MRI overestimated tumor size by 0.35 cm (95% confidence interval [95% CI], - 0.11 - 0.81 p = NS, whereas US underestimated it by -0.82 cm (95%CI, -1.01 - -0.63; p <0.001).
  • MRI measurement of the actual tumor size showed a significant correlation (r = 0.36, 95%, 0.06 - 0.61 p = 0.02) and confirms more accuracy in determining tumor size.
  • Both mammography and USG have a tendency to underestimate tumor size.
  • The use of magnetic resonance imaging would help in the accurate assessment of the tumor size influencing the choice of oncologic treatment and better predicting the prognosis of the patient.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964665.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Al-Sukhni E, Ridgway PF, O'Connor B, McLeod RS, Swallow CJ: Extent of resection for curable colorectal cancer in young patients: A 27-year experience at a tertiary care centre. J Clin Oncol; 2009 May 20;27(15_suppl):e15059

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e15059 Background: Patients diagnosed with colorectal cancer (CRC) under the age of 50 have an increased lifetime risk of developing metachronous primary tumours.
  • Factors contributing to complete resection were site of disease (colon), IBD, and family history of CRC (Table).
  • Four patients (2.6%) who underwent segmental resection developed metachronous disease at a median of 66.38 months post resection.
  • The authors support this pragmatic approach while more sophisticated estimates of tumor biology are being developed to guide the decision for more extensive prophylactic resection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964525.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Gottschling S, Kuner R, Granzow M, Chang Xu E, Muley T, Hoffmann H, Dienemann H, Eckstein V, Ho AD, Thomas M, Meister M: The individuality of tumor-stroma interaction in non-small cell lung cancer: Insights from functional and molecular analyses. J Clin Oncol; 2009 May 20;27(15_suppl):11115

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The individuality of tumor-stroma interaction in non-small cell lung cancer: Insights from functional and molecular analyses.
  • : 11115 Background: Tumor-stroma interaction plays a significant role for malignant growth.
  • Results from prostate and breast cancer rodent models show cancerogenic properties of tumor-associated and genetically altered stromal cells (SC) when combined with initiated or normal epithelium (Olumi et al., Cancer Res 1999, Kuperwasser et al., PNAS 2004).
  • However, data on the mechanisms and sequels of tumor-stroma interaction in lung cancer are scanty.
  • METHODS: Here, we analyzed the functional and molecular sequels of cross-talk between the non-small cell lung cancer (NSCLC) cell lines A549, H23, and H1703 and primary stromal cells (SC) derived from matched normal lung tissue and tumors of newly diagnosed NSCLC patients.
  • Tumor cells were kept in a non-contact co-culture system with SC and analyzed for alterations in proliferation, colony formation, migration, adhesion, invasion, chemosensitivity and gene expression by Affymetrix HG U133 Plus 2.0 arrays.
  • RESULTS: Exposure to SC altered cellular functions and gene expression profiles related to tumor growth, metastasis and response to therapy.
  • Each cell line showed individual alterations that were hierarchically governed by the (1) type of tumor cell, (2) the SC donor and his histology (3) and the local origin of the SC (normal lung tissue vs. tumor-associated).
  • CONCLUSIONS: This in vitro model demonstrates an individual pattern of tumor-stroma interaction in NSCLC that is determined by both, the properties of the tumor cells and those of the stromal environment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963495.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Wilking NE, Jönsson B: The access to oncology drugs in France, Germany, Italy, Spain, and the United Kingdom: A comparison based on data from 1998 to 2007. J Clin Oncol; 2009 May 20;27(15_suppl):6525

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The access to oncology drugs in France, Germany, Italy, Spain, and the United Kingdom: A comparison based on data from 1998 to 2007.
  • : 6525 Background: Drugs constitute a key element in the treatment of solid tumors and in haematology.
  • We have analysed the access and uptake of oncology drugs in 27 countries over a 10 year period (1998-2007) based on sales data provided by IMS Health ( www.comparatorreports.se ).
  • METHODS: In this special analysis we study a set of "mature" cancer drugs ( irinotecan, aromatase inhibitors (AIs), oxaliplatin, docetaxel, rituximab, gemcitabine, trastuzumab and imatinib) available in 2002 or before and a set of "new" cancer drugs (bortezomib, cetuximab, bevacizumab, pemetrexed, erlotinib, sorafinib, sunitinib and dasatinib) available in 2003 or later.
  • The "mature" drugs have been selected based on the fact that they have been available for a long period of time (at least 5 years) and that there is accumulated evidence based on clinical trials, epidemiological studies and clinical experience that they have had a major and clinically relevant impact on the outcome in different areas of oncology.
  • The pattern of use of "new drugs" follows that of "mature drugs", but the very low use of new drugs in UK is noticeable.
  • CONCLUSIONS: The similarity in use of both "mature" and "new" oncology drugs indicate that differences in access, found for example between France and UK, is related to health care system factors rather that evidence on outcome of use of the drugs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964031.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Plotkin SR, Singh M, Cai W, O'Donnell C, Esparza S, Smith MJ, Harris GJ, Muzikansky A, Bredella MA, Kassarjian A: Whole-body MRI evaluation of tumor burden in the neurofibromatosis tumor suppressor syndromes. J Clin Oncol; 2009 May 20;27(15_suppl):2074

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Whole-body MRI evaluation of tumor burden in the neurofibromatosis tumor suppressor syndromes.
  • The prevalence of internal tumors is not known because current estimates are based on regional MRI scans that may not detect occult tumors.
  • A rapid and sensitive method to detect internal tumors is highly desirable since they can cause neurologic dysfunction, compress vital structures, or transform into malignant tumors.
  • The number and type of tumors (discrete vs. plexiform) were identified by a board-certified radiologist and tumor volume was calculated using semi-automated analysis.
  • Sixty-one percent of subjects had ≥1 internal tumor.
  • The median number of tumors in affected individuals was 5 (range, 1 to 63 tumors).
  • Overall, the legs harbored the greatest number of tumors (33%), followed by the pelvis (18%), thorax (15%), abdomen (12%), arms (10%), and head/neck (7%).
  • Only 40% of internal tumors were classified as plexiform yet these tumors contributed 78% of the tumor burden by volume.
  • CONCLUSIONS: WBMRI scan is a powerful tool to evaluate the number, size, and distribution of internal tumors in patients with neurofibromatosis.
  • In addition, WBMRI may prove useful in identifying individual patients at high risk for complications (such as neurologic dysfunction or malignant transformation) due to heavy internal tumor burden and in determining the efficacy of antitumor drugs in this unique patient population.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964382.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Del Maestro RF, Siu V, Seyed Sadr M, Alshami J, Sabau C, Seyed Sadr E, Samani A, Assadian S, Greaves K, Pouliot J: The temozolomide O6-methylguanine-DNA methyltransferase (MGMT) study: A phase II trial to evaluate the effect of low-dose preoperative neoadjuvant temozolomide on brain tumour MGMT activity in glioma patients. J Clin Oncol; 2009 May 20;27(15_suppl):e13027

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The temozolomide O6-methylguanine-DNA methyltransferase (MGMT) study: A phase II trial to evaluate the effect of low-dose preoperative neoadjuvant temozolomide on brain tumour MGMT activity in glioma patients.
  • : e13027 Background: Epigenetic methylation of the O6-methylguanine-DNA methyltransferase (MGMT) DNA repair gene promoter in tumor tissue from glioblastoma multiforme patients is associated with improved survival after treatment with radiotherapy plus concomitant and adjuvant temozolomide (TMZ).
  • We hypothesized that MGMT promoter methylation mosaicism exists in glial tumors and would affect response to TMZ.
  • Twenty-three patients with brain tumors detected by MRI scan and suspected to be gliomas were evaluated.
  • The primary goal of the study was to evaluate the effect of TMZ 75 mg/m<sup>2</sup> daily prior to surgery on the brain tumor MGMT expression.
  • Secondary endpoints included safety, tolerability, and MGMT promoter methylation mosaicism in glial tumors.
  • Samples were obtained from multiple regions of each tumor intra-operatively and were analyzed by methylation specific PCR.
  • RESULTS: Our results on MGMT promoter methylation demonstrate that three groups of patients can be identified: Type I: all sites assessed in the tumor demonstrate no methylation of the MGMT promoter; Type II: all sites demonstrate high levels of MGMT promoter methylation; and Type III: a mixed promoter methylation pattern is observed.
  • 2) glial tumors can have very heterogeneous areas of MGMT promoter methylation; and 3) three patterns of MGMT promoter methylation can be discerned.
  • This experimental paradigm may be a useful experimental platform for the assessment of the effect of new drugs at the tumor level.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962800.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Boku N, Yamazaki K, Yamamoto N, Takahashi T, Fukutomi A, Miyazaki M, Satoh T, Okamoto I, Nakagawa K, Fukuoka M: Phase I study of nimotuzumab, a humanized anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody in patients with solid tumors in Japan. J Clin Oncol; 2009 May 20;27(15_suppl):e14574

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of nimotuzumab, a humanized anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody in patients with solid tumors in Japan.
  • : e14574 Background: Nimotuzumab, a humanized IgG1 monoclonal antibody targeting EGFR, has been used in head & neck cancer or malignant glioma outside Japan, and MTD including severe skin rash were not observed up to 800mg/body.
  • METHODS: Pts with advanced solid tumors having no available standard therapy were enrolled.
  • Blood, skin samples before treatment and after 4th infusion and pre-treatment tumor were collected for PD analysis.
  • A correlation between anti-tumor activity and EGFR amplification was speculated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963651.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Shayne M, Culakova E, Poniewierski MS, Wolff DA, Lyman GH: Risk factors for in-hospital mortality and prolonged length of stay in older patients with solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):9550

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for in-hospital mortality and prolonged length of stay in older patients with solid tumors.
  • This study identified 386,377 older hospitalized patients with various solid tumors.
  • Additional risk factors associated with IHM included metastatic disease, active infection, neutropenia, renal disease, lung disease, arterial and venous thromboembolism, congestive heart failure, hepatic disease, and RBCT.
  • CONCLUSIONS: Improving trends in LOS and IHM for older patients with solid tumors were observed over time in this study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963598.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Kuter I, Anderson E, Emeribe U, Finlay P, Nicholson R, Gee J: Comparison of methods for detection of fulvestrant-induced changes in breast tumor estrogen and progesterone receptor expression in a neoadjuvant trial (NEWEST). J Clin Oncol; 2009 May 20;27(15_suppl):e11602

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of methods for detection of fulvestrant-induced changes in breast tumor estrogen and progesterone receptor expression in a neoadjuvant trial (NEWEST).
  • : e11602^ Background: Fulvestrant downregulates breast tumor estrogen and progesterone receptor (ER and PgR) levels in a dose-dependent manner.
  • Using an Automated Cellular Imaging System (ACIS), NEWEST reported that 4-wks' treatment with fulvestrant high-dose (HD, 500mg/month+500mg on Day 14 of Month 1) significantly reduced ER levels in primary breast tumors v approved-dose (AD, 250mg/month).
  • To allow comparison with previous studies, a non-automated H-score assessment was performed and compared with ACIS.
  • METHODS: ER and PgR H-scores were derived by manual assessment of % tumor cells in each of 5 staining categories (negative, very weak, weak, moderate, strong) in the same sections scored by ACIS.
  • (2) is the inventor of a unique technology or treatment being evaluated in the clinical trial; or (3) is involved in international clinical oncology research and has acted consistently with recognized international standards of ethics in the conduct of clinical research.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961051.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Hepp P, Rack B, Schneider A, Rezai M, Tesch H, Beck T, Söling U, Lichtenegger W, Beckmann MW, Janni W: Effects of G-CSF on circulating tumor cells (CTC) and CA 27.29 in breast cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):11027

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of G-CSF on circulating tumor cells (CTC) and CA 27.29 in breast cancer patients.
  • : 11027 Background: Some recent publications indicated that the use of G-CSF could be connected to an increase in CTC as well as elevated levels of tumor markers such as CA 27.29.
  • This could be a possible explanation for the often observed increase of tumor markers after CHT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963970.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Beyer J, Hackenthal M, Lorch A, Neubauer A, Dieing A, Rick O, Hartmann JT, Bokemeyer C: High-dose chemotherapy (HDCT) as second salvage treatment in patients with multiple relapsed or refractory germ cell tumors. J Clin Oncol; 2009 May 20;27(15_suppl):5082

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose chemotherapy (HDCT) as second salvage treatment in patients with multiple relapsed or refractory germ cell tumors.
  • : 5082 Background: To determine the activity of high-dose chemotherapy (HDCT) as intensification of second salvage treatment (SST) in patients with multiple relapsed germ-cell tumors (GCT).
  • METHODS: Databases in Berlin and Marburg (Germany) on patients treated with HDCT between 1989 and 2008 for germ-cell tumors were screened.
  • Histology was pure seminoma in 5/49 (10%) patients and non-seminoma or mixed histologies in 44/49 (90%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964281.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Ursu R, Carpentier A, Metellus P, Barrie M, Meng Y, Laigle-Donadey F, Tibi A, Chinot O, Carpentier AF: Phase II trial of intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma. J Clin Oncol; 2009 May 20;27(15_suppl):2043

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • When injected locally, they can induce tumor rejection in animal models.
  • The percentage of patients without tumour progression at 6 months after inclusion was the primary endpoint.
  • CpG-28 reached up to 79 ng/mL at the end of infusion in one patient.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964650.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Hussain R, Jamshed A, Rehman K, Iqbal H, Azhar R, Faruqui Z, Ahmed Q: Function preservation with multimodality treatment in locally advanced oral tongue cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e17051

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pretreatment AJCC stage as assessed on MRI was T2N+ (tumour crossing midline) 13%, T3N0 20%, T3N+ 47%, and T4N+ 20%.
  • Four to six weeks following second cycle of chemotherapy local excision of residual primary tumor with ipsilateral modified neck dissection was performed.
  • Patients with ypN+ disease received concomitant 3 weekly cisplatin 75 mg/m<sup>2</sup> with radiation.
  • RESULTS: Overall and disease free survival at 20 months was 60%.
  • Twelve patients (80%) are alive and 3 patients (20%) have died of disease at 9, 14 and 14 months (locoregional failure 1 and distant metastasis 2 patients).
  • In patients alive without disease assessment of deglutition and speech at the time of last follow up showed all patients on full oral diet with spontaneous intelligible speech.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961816.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Goel R, Chen E, Welch S, Laurie S, Siu L, Jonker D, Srinivasan R, Wang L, Ivy P, Oza A, Princess Margaret Hospital Phase II Consortium: Phase I study of E7389/gemcitabine combination in patients with advanced solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e13509

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of E7389/gemcitabine combination in patients with advanced solid tumors.
  • Gemcitabine (G) is a nucleoside analogue clinically active in several human tumours.
  • These two drugs exhibit synergistic cytotoxic effects against the H522 non-small cell lung cancer (NSCLC) xenografts.
  • METHODS: A phase I study of these two drugs in combination was initiated in patients with advanced solid tumours.
  • Two prior chemotherapy regimens for metastatic disease were allowed.
  • RESULTS: Patient characteristics: male 11/female 10; median age 59 (range 28-84); performance status 0 /1/2: n=1/13/7; prior chemotherapy 21, prior radiotherapy 7, prior immunotherapy 1; tumour types: ovarian cancer 3, endometrial cancer 3, NSCLC 3, gastric/esophageal adenocarcinoma 3, miscellaneous 9.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961270.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Hörsch D, Prasad V, Ambrosini V, Hommann M, Fanti S, Baum RP: Detection of unknown primary neuroendocrine tumors (CUP-NET) using &lt;sup&gt;68&lt;/sup&gt;Ga DOTA-NOC receptor PET/CT. J Clin Oncol; 2009 May 20;27(15_suppl):4599

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of unknown primary neuroendocrine tumors (CUP-NET) using <sup>68</sup>Ga DOTA-NOC receptor PET/CT.
  • : 4599 Background: This bi-centric study aimed at determining the role of receptor PET/CT using <sup>68</sup>Ga-DOTA-NOC in the detection of undiagnosed primary sites of neuroendocrine tumours (NETs).
  • The SUVmax of the unknown pNET and SI-NET were significantly lower (p< 0.05) as compared to the ones with known primary tumour sites.
  • In 4/59 patients the primary tumour was subsequently resected (2 pancretic, one ileal and one rectal tumour).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963110.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Endo M, Watanabe H, Yamamoto S, Yamamoto N, Ohe Y, Tamura T: Impact of revised lymph node measurement rules in the new RECIST version 1.1 on the tumor response evaluation in patients with advanced lung cancer. J Clin Oncol; 2009 May 20;27(15_suppl):7567

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of revised lymph node measurement rules in the new RECIST version 1.1 on the tumor response evaluation in patients with advanced lung cancer.
  • : 7567 Background: The new RECIST ver.
  • Lymph nodes that are at least 10mm but less than 15mm in short axis may be pathologic and can be considered as non-measurable/non-target lesions (not measured).
  • METHODS: Two radiologists independently reviewed the objective tumour response of 305 patients (pts) with advanced lung cancer who had primary lesion and lymph node metastases as target lesions measured more than 10 mm in the longest diameter.
  • The tumor responses were divided into four categories (CR, PR, SD, PD), following proportion of agreement and estimation of kappa statistics between two the criteria as agreement measure.
  • Out of the 108 pts with PR by ver.1.0, 8.3 % were downgraded to SD and 1.0 % was categorized as PD by ver.1.1.
  • On the other hand, out of the 190 pts with SD by ver.1.0, 6.3 % were upgraded to PR and 8.9 % were downgraded to PD by ver.1.1.
  • CONCLUSIONS: No significant impact was observed for the revised lymph node measurement rules in the new RECIST ver.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963363.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Lou Dr W, Niu G: BRSK2 expression as a prognosis marker in pancreatic cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):e15603

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The research of factors related to oncogenesis, tumor infiltration and metastasis is valuable.
  • As a member of AMPK, BRSK2 is found to be expressed in human pancreatic cell line and facilitate the tumor cell survival on glucose starving.
  • In order to examine the expression of BRSK2 in human pancreatic cancer and explore the underline clinical implication, human pancreatic tissue was examined immunohistochemically Correlation of tumor biological behavior, prognosis and BRSK2 expression was examined.
  • METHODS: Seventy nine resected tumor specimens were collected.
  • Semi-quantitative analysis was employed to compare the expression intensity and content of BRSK2 in tumor issues, peri-tumorous tissue and normal pancreatic tissue.
  • Possible relationship of tumors differentiation, TNM stage, presence or absence of vessel and neural infiltration were explored with BRSK2 expression.
  • RESULTS: BRSK2 was weakly expressed in normal pancreatic tissues and peri-tumor tissues, including the islet and minor ducts.
  • Tumors with lymphatic metastasis, distant metastasis, neural invasion and later TNM stages showed stronger expression of BRSK2.
  • CONCLUSIONS: BRSK2 is up-regulated in pancreatic cancer; the expression of BRSK2 is correlated with tumor biological behavior and patient's prognosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962679.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Toumpanakis C, Quigley A, Srirajaskanthan R, Marelli L, Singhrao T, Meyer T, Buscombe J, Caplin ME: 90-Yttrium-DOTA-octreotate for the treatment of advanced neuroendocrine tumors. J Clin Oncol; 2009 May 20;27(15_suppl):4594

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 90-Yttrium-DOTA-octreotate for the treatment of advanced neuroendocrine tumors.
  • : 4594 Background: The expression of somatostatin receptors (SSTR) on Neuroendocrine Tumors (NETs) has led not only to tumour visualization utilizing SSTR scintigraphy, but also to the development of receptor-targeted radionuclide therapy.
  • Isotopes such as 111-Indium, 90-Yttrium and 177-Lutetium are linked to somatostatin analogues and then internalized by tumour cells.
  • In all patients, the tumours had shown good uptake either in the OctreoScan or in the Ga-68 octreotate PET scan.
  • 29/89 patients included a cycle of intra-arterial therapy with mean dose/cycle 2090 MBq for large volume liver disease.
  • RESULTS: In all patients the post treatment scintigraphy demonstrated good uptake and localization by the tumors.
  • Utilizing RECIST criteria, 50/89 (56%) had disease stabilization (SD) of previously progressive disease and 7 (8%) had partial response (PR).
  • 31/89 (35%) had continued tumor progression.
  • The SD/PR (n=57) group had sustained response for median 17.2 months.
  • CONCLUSIONS: 90Y-DOTA-octreotate is a well-tolerated and safe treatment for patients with progressive neuroendocrine tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963114.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Marginean EC, Torlakovic G, Neufeld H, Torlakovic E: Association of upregulated GATA-4 transcription factor colorectal adenocarcinoma with metastatic and primary tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e15093

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of upregulated GATA-4 transcription factor colorectal adenocarcinoma with metastatic and primary tumors.
  • Nuclear factor-B (NF-B) activation was shown to promote the growth of the colon tumors in experimental models and was correlated with tumor angiogenesis and progression in human colorectal cancer.
  • The benign colonic mucosa and the matching metastatic tumors of the same patients were also included in the study.
  • RESULTS: GATA-4 was expressed in 32% of colorectal adenocarcinoma, but not in benign colonic mucosa (p=0.0001, Chi-Square).
  • NF-B activation was not present in any of the samples of benign colonic mucosa, but it was detected in 64% adenocarcinomas (p<0.0001, Chi-Square).
  • CONCLUSIONS: GATA-4, a developmental transcription factor is not expressed by normal colonic mucosa, but is present in 1/5 of primary tumors that gave rise to distant metastases and in almost 1/2 of their respective metastases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964606.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Voit CA, van Akkooi AC, Schaefer-Hesterberg G, Schoengen A, Sterry W, Eggermont AM: Correlation of ultrasound criteria for detection of melanoma metastases in the sentinel lymph node (SN) with tumor burden and survival. J Clin Oncol; 2009 May 20;27(15_suppl):9015

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of ultrasound criteria for detection of melanoma metastases in the sentinel lymph node (SN) with tumor burden and survival.
  • Here we show how these patterns correlate with tumor burden, progression of disease and survival.
  • US images were prospectively scored for 6 morphologic criteria.
  • Sensitivity, specificity and negative/positive predictive value (NPV and PPV) of combinations of US patterns were calculated and correlated with tumor burden and survival.
  • Balloon Shape (BS) & Loss of Central Echoes (LCE) are often linked (up to 83%) and are late signs correlating with high tumor load.
  • In contrast the presence of Peripheral Perfusion (PP) is an early sign, correlating with small tumor load.
  • BS/LCE was a late sign correlating with high tumor load, fast progression and a high HR (5.50).
  • PP alone was an early sign correlating with small tumor load, slow progression, and a low HR (2.19).
  • CONCLUSIONS: BS and/or LCE indicate high tumor load, PP alone indicates small tumor load in the SN.
  • These US-criteria identify the SN tumor burden correctly prior to SN biopsy in 75% - 90% of pts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962376.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Sekulic A, Miller A, Barrett M, Ejadi S, Mengos A, Pockaj B, Markovic S: Identification of targetable cellular subsets within melanoma tumors. J Clin Oncol; 2009 May 20;27(15_suppl):9082

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of targetable cellular subsets within melanoma tumors.
  • : 9082 Background: Human tumors, including melanoma, are complex mixtures of individual, molecularly distinct subpopulations, or clones of cancer cells.
  • Effective cancer therapy will likely require targeting of all tumor subsets within a given cancer.
  • Understanding the tumor complexity and the ability to identify points of therapeutic vulnerability within the individual tumor subsets will be essential for development of effective personalized cancer therapies.
  • METHODS: We have developed an approach that combines identification of individual tumor subsets using a multiparameter nuclear flow cytometry coupled with a high-resolution genomic analysis using the array-based comparative genomic hybridization (aCGH).
  • Melanoma nuclei were isolated from tumor tissues and subjected to flow cytomery using melanocyte-specific antibodies (to separate melanoma cells from stroma) and DNA content, to separate individual tumor subpopulations.
  • RESULTS: We initially demonstrate the feasibility of the outlined approach by successful separation of melanoma from stromal nuclei and separation of individual melanoma nuclear subpopulations by DNA content. aCGH analysis of the DNA derived from isolated tumor subpopulations allowed successful identification of potentially targetable molecular aberrations in individual subsets of tumor cells.
  • Notably, such aberrations were often not detected in unsorted, bulk tumors analyzed by the same high-resolution aCGH approach.
  • CONCLUSIONS: We demonstrate a feasible approach to in-depth molecular analysis of tumor subpopulations within a clinical cancer tissue.
  • This approach allows identification of potentially targetable molecular aberrations within individual tumor subsets, thus opening a possibility for a broad tumor targeting through design of individually-tailored therapeutic approaches.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962203.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Launay-Vacher V, Janus N, Spano J, Gligorov J, Ray-Coquard I, Beuzeboc P, Morere J, Pourrat X, Deray G, Oudard S: Impact of renal insufficiency on cancer survival: Results of the IRMA-2 study. J Clin Oncol; 2009 May 20;27(15_suppl):9585

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Data included: sex, age, weight, serum creatinine, type of tumour, metastasis (bone and/or visceral).
  • RI was strongly linked to mortality (p<0.0001), when analysing all type of patients and tumors.
  • When the same analysis was performed for non-metastatic patients (n=2382), RI was also associated with mortality (p<0.0001).
  • Finally, 2 Cox models adjusted for sex, age, and the 5 main types of tumor were associated with a significant increase in the risk of death for patients with aMDRD<60 as compared to patients without ( Table ).
  • CONCLUSIONS: IRMA-2 is the first large scale study reporting an association between RI and a reduced cancer survival.
  • Cancer patients with aMDRD<60 seemed to be more at risk of death for the following 2 years even in non metastatic patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963707.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Wang EM, Pan L, Wang BJ, Zhang N, Zhou LF, Dong YF, Dai JZ, Cai PW, Chen H: The long-term results of gamma knife radiosurgery for hemangioblastomas of the brain. J Neurosurg; 2005 Jan;102(s_supplement):225-229

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eighteen patients presented with multiple tumors and 17 with a solitary tumor.
  • Twenty-one patients had von Hippel-Lindau (VHL) disease.
  • The mean tumor diameter was 13 mm (range 5-55 mm).
  • The mean prescription dose was 17.2 Gy (range 12-24 Gy) at the tumor margin.
  • For tumors close to or within the brainstem a prescription dose of 12 to 13 Gy was used.
  • At the most recent follow up, 29 patients were alive, six were dead, and satisfactory tumor control had been achieved in 29.
  • Eight patients underwent open surgery because of tumor-associated cyst enlargement or the development of new tumors after GKS.
  • Seven patients developed new tumors and five of them required a second GKS.
  • The 1-year tumor control rate was 94%; 2 years, 85%; 3 years, 82%; 4 years, 79%; and 5 years, 71%.
  • Histopathology showed that no tumor cells were found and there was degeneration and necrosis in a tumor nodule 48 months after GKS with a prescription dose of 18 Gy.
  • CONCLUSIONS: Gamma knife surgery was a useful choice for small- or medium-sized, solid HAB in the long term, especially when the tumor margin dose was 18 Gy.
  • Although GKS can treat multiple tumors in a single session, for HABs associated with VHL disease, GKS faces the dual problems of tumor recurrence or development of a new tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28306468.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; gamma knife surgery / hemangioblastoma / von Hippel—Lindau disease
  •  go-up   go-down


57. Kiyohara H, Kato S, Ohno T, Ohkubo Y, Tamaki T, Kamada T: Carbon ion radiotherapy for malignant melanoma of female genital organs. J Clin Oncol; 2009 May 20;27(15_suppl):e16548

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carbon ion radiotherapy for malignant melanoma of female genital organs.
  • : e16548 Background: Malignant melanoma of the female genital organs is a very rare tumor and resistant to conventional photon radiotherapy.
  • We report six cases of female genital malignant melanoma those were well controlled locally by carbon ion radiotherapy (CIRT).
  • METHODS: Between November 2004 and October 2008, six patients with unresectable female genital malignant melanoma were treated with CIRT.
  • Four patients had previously untreated locally invasive tumors and other two had locally recurrent tumors after surgery and adjuvant chemotherapy.
  • The tumor located in the vagina (4 patients), both the cervix and the vagina (1 patient), or both the vagina and the vulva (1 patient).
  • All tumors completely responded to CIRT.
  • The four patients without distant metastasis were alive with no evidence of disease for 9-20 months after CIRT.
  • The two patients with distant metastases died from metastatic disease 13 and 18 months after CIRT, respectively.
  • CONCLUSIONS: CIRT achieved favorable local tumor control without developing severe acute and late toxicity in the treatment of unresectable malignant melanoma of the female genital organs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960818.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Wirths S, Malenke E, Wiesner T, Buehring H, Hartmann J, Kopp HG: Detection of MSC-like cells in soft tissue sarcoma cell lines and primary tumors. J Clin Oncol; 2009 May 20;27(15_suppl):11000

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of MSC-like cells in soft tissue sarcoma cell lines and primary tumors.
  • : 11000 Background: Soft tissue sarcomas (STS) are a heterogeneous group of mesodermal tumors hypothetically originating from mesenchymal stem cells (MSC).
  • METHODS: To target rare human cell populations including MSCs, an exclusive antibody panel was developed.
  • The target antigens include platelet-derived growth factor receptor-β (CD140b), HER-2/erbB2 (CD340), TNFRSF16 (CD217), frizzled-4 (CD344), the recently described W8B2 antigen, as well as several surface antigens identified by novel antibodies.
  • To define the expression pattern of MSC-markers in STS, both cell lines and primary tumor samples in suspension and in snap frozen sections were investigated.
  • To reveal functional differences between identified rare tumor populations single cell proliferation kinetics were investigated after FACS-sorting.
  • RESULTS: All cell lines und primary tumor samples revealed expression of selected markers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964050.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Zigeuner R, Hutterer G, Chromecki T, Rehak P, Pummer K: Macroscopic versus microscopic vascular tumour invasion in patients with clear cell renal cell carcinoma: Does it make a difference? J Clin Oncol; 2009 May 20;27(15_suppl):5093

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Macroscopic versus microscopic vascular tumour invasion in patients with clear cell renal cell carcinoma: Does it make a difference?
  • METHODS: The pathology reports of 2333 consecutive patients operated between 01/1984 and 12/2006 were re-evaluated with regard to histological subtype, pT categories (TNM 2002), tumor grade, lymph node status, tumor size, presence of necrosis, and vascular invasion (defined as either absent, microscopic, or macroscopic).
  • RESULTS: Out of 1797 CC-RCC-patients fulfilling the selection criteria, 1754 (97.6%) with complete data including follow-up were evaluated.
  • Microscopic and macroscopic invasion was noted in 99 (5.6%) and 278 (15.8%) tumours, respectively.
  • Multivariate analysis proved pT-categories, grade, node status, size, necrosis and overall vascular invasion (p < 0.0001; RR = 2.09, 95%CI = 1.46-2.98) as independent predictors of metastatic disease.
  • Microscopic invasion was an independent predictor of metastatic disease, whereas macroscopic invasion which is directly related to categories pT3b/c was not.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964295.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Epenetos AA, Kousparou C, Stylianou S: Inhibition of Notch and tumor regression. J Clin Oncol; 2009 May 20;27(15_suppl):e14623

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of Notch and tumor regression.
  • : e14623 Background: Notch signaling is an evolutionary-conserved pathway in vertebrates and invertebrates which is involved many developmental processes, including cell fate decisions, apoptosis, proliferation, and stem-cell self renewal.
  • Increasing evidence suggests that the Notch signaling pathway is frequently up regulated in many forms of cancer including acute T-cell lymphoblastic leukemia, cervical, prostate, lung, breast and others.
  • This novel fusion protein has been tested for its ability to target tumor cells in vitro and in vivo.
  • Furthermore, TR4 inhibits human mammary and colon xenograft tumor growth and metastases in immuno deficient mice.TR4 presence and activity was also detected in the brains of treated animals demonstrating that TR4 can cross the blood-brain barrier and potentially eliminate brain tumors and metastases, unlike other anticancer drugs and biological such as monoclonal antibodies that cannot cross the blood brain barrier.
  • TR4 was found to be non- immunogenic following repeat administration in healthy animals.
  • CONCLUSIONS: The TR4 protein, a Notch inhibitor, can induce tumor regression and resolution of breast and colon cancer xenografts.
  • It is non- immunogenic following repeat administration and has acceptable toxicity profile.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964214.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. LoRusso P, Markman B, Tabernero J, Shazer R, Nguyen L, Heath E, Patnaik A, Papadopoulos K: A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765, a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):3502

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765, a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced solid tumors.
  • XL765 has shown dose-dependent target modulation and tumor growth inhibition or shrinkage in multiple human xenografts.
  • Tumor response is assessed by RECIST every 8 weeks.
  • Grade > 2 increase in transaminases, including one possibly related serious adverse event of Grade 4, occurred in 3 of 7 pts at 120 mg bid.
  • Non-specific neurological complaints (1) and rash (1) were the DLTs that occurred at 100 mg qd.
  • Robust pharmacodynamic modulation of PI3K pathway signaling in PBMCs, hair follicles, skin, and tumors was evident following administration of XL765.
  • Five pts had durable stable disease (> 3 months): appendiceal cancer (15 mg bid) 8 cycles; RCC (15 mg bid) 4 cycles; NSCLC (30 mg bid) 4 cycles; mesothelioma (60 mg bid) 10 cycles; CRC (100 mg qd) 6 cycles.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961282.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Lu L, Schafer P, Bartlett JB: Inhibition by lenalidomide of growth factor and hypoxia-induced signaling in endothelial and epithelial tumor cells, and effects within the tumor cell microenvironment. J Clin Oncol; 2009 May 20;27(15_suppl):e14620

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition by lenalidomide of growth factor and hypoxia-induced signaling in endothelial and epithelial tumor cells, and effects within the tumor cell microenvironment.
  • It has direct anti-proliferative activity in hematological cells but there is no evidence of direct activity in solid tumor cells.
  • In solid tumors, lenalidomide is being advanced in combination with other agents to take advantage of its immune-enhancing properties in combination with direct anti-tumor agents.
  • Lenalidomide studies in CLL and MM suggest that it may also attenuate pro-survival signals generated by interaction of stroma with the malignant cell itself.
  • Lysophosphatidic acid (LPA) is a key pro-survival factor present at high levels within the ascites of ovarian cancer patients which confers increased tumor invasiveness and reduced survival.
  • Hypoxia-induced factor (HIF)-1α is the key initiator of angiogenesis and tumor invasiveness.
  • METHODS: The effect of lenalidomide on growth factor-induced Akt phosphorylation was investigated in endothelial cells, NHL cells, and ovarian cancer cells in vitro.
  • RESULTS: Lenalidomide inhibited growth factor-induced Akt phosphorylation.
  • Treatment of ovarian tumor cells with LPA increased tumor cell invasiveness via enhanced p-Akt.
  • Lenalidomide strongly inhibited invasion and p-Akt (at S308 but not T473) in a dose-dependent manner.
  • Hypoxic endothelial cells and epithelial tumor cells showed enhanced HIF-1α expression.
  • Lenalidomide inhibited hypoxia-induced HIF-1α expression by endothelial cells and by epithelial tumor cells, including prostate, breast, pancreatic, renal and ovarian tumor cells.
  • CONCLUSIONS: Lenalidomide may act within the tumor microenvironment to inhibit key signals of tumor cells survival, growth, and invasiveness.
  • These studies support the potential utility of lenalidomide in combination with other agents in the treatment of patients with solid tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964203.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Dhani NC, Tu D, Parulekar W, Seymour L, Moore MJ: A retrospective analysis of tumor size (TS) as a continuous rather than discrete variable in advanced pancreatic cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15565

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A retrospective analysis of tumor size (TS) as a continuous rather than discrete variable in advanced pancreatic cancer.
  • : e15565 Background: Objective "response rate" (RR) dichotomizes patients into categories of "response" (complete or partial) and "non-response".
  • This ignores a lot of data captured within the trial on tumor size changes, and may miss clinically important effects on tumor growth may occur in the absence of a response.
  • METHODS: Tumor size data from 2 randomized controlled trials in advanced pancreatic cancer conducted by NCIC.CTG were analyzed; NCIC.PA1 randomized patients to BAY12-9566 (MMPI) or Gemcitabine (Gem) and demonstrated a large and significant survival (OS) benefit for Gem (6.7 vs 3.4 months), NCIC.PA.3 randomized patients to Gem ± Erlotinib and showed a modest OS benefit for the combination (HR =0.81).
  • The difference in logarithms (d-LTS) from baseline to 8 weeks was calculated to indicate change in tumor size.
  • Analysis on the 1<sup>st</sup> 130 patients yielded similar results (p=0.02) Conclusions: Tumor size changes may be a reasonable endpoint for screening efficacy trials in advanced pancreatic cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962325.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. O'Dorisio MS, Navalkele P, O'Dorisio TM, Lynch CF: Neuroendocrine tumors in children and young adults: Incidence, survival, and prevalence in the United States. J Clin Oncol; 2009 May 20;27(15_suppl):e22120

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroendocrine tumors in children and young adults: Incidence, survival, and prevalence in the United States.
  • : e22120 Background: Neuroendocrine tumors (NET) arising from the diffuse endocrine system are thought to be quite rare in children and young adults.
  • However, a surprising number of young people have been referred to our neuroendocrine tumor clinic and the NCI has targeted NET as a high priority for development of new diagnostic and therapeutic options.
  • ICD-9 codes related to neuroendocrine tumors and to neuroblastoma were characterized as to patient age, gender, racial and ethnic background, stage, grade, histology, incidence, survival, and prevalence.
  • RESULTS: Neuroendocrine tumors occur more often in females among children and young adults with the most common sites being bronchial, ovarian, and breast.
  • The overall incidence of neuroendocrine tumors was lower than for neuroblastoma in the age range 0-30 years.
  • However, the 30 year limited prevalence of neuroendocrine tumors in the 9 SEER registries was 698 compared to 881 for neuroblastoma.
  • This extrapolated to over 7000 children and young adults with neuroendocrine tumors across the United States.
  • Survival rate of young people with neuroendocrine tumors declined from 84% in 1975-1986 to 80% in the 1987-2004 era.
  • CONCLUSIONS: These results indicate that neuroendocrine tumors constitute an unrecognized cancer threat to children and young adults.
  • Survival of children and young adults with neuroendocrine tumors has decreased over the past 30 years in the United States.
  • We recommend the establishment of centers of care for children and young adults diagnosed with neuroendocrine tumors with the expectation that earlier diagnosis coupled with targeted therapies will decrease the incidence of metastatic disease and improve survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963558.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Eralp Y, Basaran G, Dogan M, Dincol D, Demirci S, Icli F, Onur H, Saip P, Topuz E, Haydaroglu A: The outcome of patients with triple negative breast cancer: Evidence for a favorable ethnic subgroup? The Turkish Oncology Group experience. J Clin Oncol; 2009 May 20;27(15_suppl):e22158

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The outcome of patients with triple negative breast cancer: Evidence for a favorable ethnic subgroup? The Turkish Oncology Group experience.
  • The aim of this study is to evaluate the outcome of non-metastatic TNBC patients in a National registry setting and identify clinical and pathologic variables associated with survival.
  • METHODS: From a retrospective registry cohort of 296 TNBC patients treated and followed between 1993-2007, we identified 248 patients with early stage disease, with follow-up of at least 12 months.
  • 5 year overall survival (OS) and disease-free survival (DFS) rates were 84±2.7 % and 69±3.3%, respectively.
  • Univariate analysis revealed locally advanced disease (p:0.0001), larger tumor size (p:0.004), nodal positivity (p<0.00001), and extent of nodal involvement as significant factors for DFS; whereas, locally advanced disease (p:0.0099) and extent of nodal involvement (p:0.018) were identified as prognostic factors with an impact on OS.
  • Multivariate analysis revealed locally advanced disease (HR: 3.3, p:0.02, 95% CI: 0.14-0.64) and extent of nodal involvement (HR:4.3, p:0.033, 95% CI: 0.059-0.88) as significant independent prognostic factors for DFS and OS, respectively.
  • It may be speculated that there may be inherent ethnic differences leading to distinctive tumor behaviour.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963549.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Francescutti V, Farrokhyar F, Tozer R, Heller B, Lovrics P, Jansz G, Kahnamoui K: Primary tumor and patient characteristics in breast cancer as predictors of adjuvant chemotherapy regimen: A regression model. J Clin Oncol; 2009 May 20;27(15_suppl):e11632

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary tumor and patient characteristics in breast cancer as predictors of adjuvant chemotherapy regimen: A regression model.
  • This study was undertaken to determine which patient and tumor characteristics are important in guiding the choice of adjuvant chemotherapy.
  • Patient and tumor characteristics were identified and chemotherapy regimens compared.
  • A p-value of < 0.05 was significant and comparisons were two tailed.
  • Indicators of choice of aggressive regimen were higher stage [OR 4.7 (CI 3.3, 6.8)], positive nodes [2.5 (1.6, 3.8)], negative PR [2.1 (1.4, 3.1)], higher grade [1.4 (1.0, 1.8)], and age [0.91 (0.88, 0.92)].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961177.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Feigl GC, Bundschuh O, Gharabaghi A, Safavi-Abassi S, El Shawarby A, Samii M, Horstmann GA: Evaluation of a new concept for the management of skull base chordomas and chondrosarcomas. J Neurosurg; 2005 Jan;102(s_supplement):165-170

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of a new concept for the management of skull base chordomas and chondrosarcomas.
  • OBJECT: Chordomas and chondrosarcomas of the skull base are rare locally invasive tumors associated with high recurrence rates.
  • The aim of this study was to evaluate the concept of microsurgical tumor volume reduction followed by early gamma knife surgery (GKS).
  • METHODS: Thirteen patients with 15 tumors were treated between October 2000 and June 2003.
  • All patients first underwent maximal tumor resection.
  • The mean postoperative tumor volume treated with GKS was 9.7 cm<sup>3</sup> (range 1.4-20.3 cm<sup>3</sup>).
  • Follow-up computerized tomography and magnetic resonance imaging examinations with volumetric tumor analysis were performed every 6 months after GKS.
  • The mean follow-up duration was 17 months during which there was only one tumor recurrence at the margin of the radiation field.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28306442.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; chondrosarcoma / chordoma / gamma knife surgery / skull base tumor / volumetry
  •  go-up   go-down


68. Zanon C, Airoldi M, Garzaro M, Raimondo L: Functional and psychological evaluation after exclusive chemoradiation therapy in oral and oropharyngeal cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e17012

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e17012 Purpose: The treatment of head and neck tumours often negatively affects speech, swallowing, body image and quality of life (QoL).
  • Late effects of CH-RT and psycho-oncological assessment included: Radiation Therapy Oncology Group (RTOG) - European Organisation for Research and Treatment of Cancer (EORTC) late radiation morbidity scoring system, DISCHE morbidity recording scheme, Hospital Anxiety and Depression Scale (HADS), Montgomery Asberg Depression Rating Scale (MADRS), Mini Mental Adjustment to Cancer (MINI MAC), and EORTC QoL Head and Neck 35.
  • Just a fair concordance in rate of depression between self- and hetero-evaluated scale was observed, with higher rates relieved by MADRS compare to HADS depression subscale using 8 or 10 cut-off (Cohen's k test = 0.401) Conclusions: Our data suggest low rates of anxiety and depression, in patients treated with CH-RT, with a different evaluation between self-evaluative and hetero-evaluative scales.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961727.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Kaiser L, Fridlyand J, Fyfe G: Baseline and change from baseline in tumor burden compared with patient outcomes. J Clin Oncol; 2009 May 20;27(15_suppl):e17530

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Baseline and change from baseline in tumor burden compared with patient outcomes.
  • : e17530 Background: The impact of baseline tumor burden (bTB) and percentage reduction in tumor burden (dTB) on patient outcome has not been systematically studied in oncology clinical trials.
  • METHODS: We analyzed 3 B and 1 T Ph 3 mBC and mCRC trials of > 1800 patients total.
  • Tumor burden and PFS are independent predictors of OS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963808.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. McCaffery I, Tolcher A, Puzanov I, Sarantopoulos J, Rosen L, Deng H, Paweletz K, Friberg G: Analysis of biomarkers during early phase clinical development of AMG 479, an investigational fully human monoclonal antibody antagonist of type 1 insulin-like growth factor receptor (IGF-1R). J Clin Oncol; 2009 May 20;27(15_suppl):3545

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of biomarkers during early phase clinical development of AMG 479, an investigational fully human monoclonal antibody antagonist of type 1 insulin-like growth factor receptor (IGF-1R).
  • : 3545 Background: AMG 479 showed anti-tumor activity in a phase 1 (P1) and phase 1b (P1b) trial (Tolcher, J Clin Oncol.
  • We sought to identify predictive markers of response to AMG 479 in these trials by analyzing pharmacodynamic (PD) markers in serum, and expression and mutations of regulators of the IGF-1R pathway in tumors.
  • METHODS: Patients (pts) had advanced solid tumors and received AMG 479 (1-20 mg/kg Q2W) in the P1 trial or AMG 479 (6 or 12 mg/kg Q2W) + panitumumab (6 mg/kg Q2W) or gemcitabine (1,000 mg/m<sup>2</sup> QW) in the P1b trial.
  • In the P1 trial, we examined relationships between tumor response (by RECIST) and:.
  • 2) somatic mutations in key genes (including K-ras, and PTEN) of the IGF-1R pathway (in archival tumors); and 3) expression of PTEN (measured by immunohistochemistry in archival tumors).
  • Baseline and PD changes in IGF-1 and IGFBP-3 were not substantially different in pts with a tumor response compared with those without a tumor response.
  • No responses have been observed in tumors that lack expression of PTEN.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961355.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Timmerman J, Betting D, Yamada R, Hurvitz S, Steward K, Said J, van Rooijen N, Kafi K: In vivo activity of rituximab-CpG oligodeoxynucleotide conjugate against rituximab-resistant human CD20+ B-cell lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):8529

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 8529 Background: The anti-CD20 monoclonal antibody rituximab (R) is a mainstay in the treatment of B cell non-Hodgkin's lymphoma (NHL), exerting anti-tumor effects via antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity, and apoptosis induction.
  • Established tumors in immunocompetent mice were treated with R plus CpG given systemically, intratumorally, or chemically linked to antibody using maleimide-sulfhydryl chemistry (D.
  • Betting et al, J. Immunol.
  • RESULTS: 5- to 7-day established tumors were completely resistant to single agent R.
  • Combining intratumoral, but not systemic administration of CpG with R resulted in tumor eradication from up to 42% of mice (p < 0.0003 vs. R alone, CpG alone, R + systemic CpG).
  • Mechanistic studies indicated that both natural killer cells and complement participated in the cure of tumors by intratumoral CpG + R, by increasing tumor cell sensitivity to complement and ADCC lysis, and by augmenting the cytotoxicity of ADCC effectors.
  • To overcome the need for repeated direct intratumoral injections and allow precise targeting of CpG to tumor cells, we chemically linked CpG to R using a cleavable linker.
  • A single i.v. injection of this R-CpG conjugate achieved eradication of established tumors from 100% of mice.
  • CONCLUSIONS: In conclusion, enhancement of R efficacy required sustained intratumoral delivery of CpG to maximize anti-tumor responses.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960908.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Aharinejad S, Thomas A, Singer C, Kubista E, Paulus P, Miksovsky A, Abraham D: Significance of serum colony-stimulating factor-1 as a breast cancer marker. J Clin Oncol; 2009 May 20;27(15_suppl):11071

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Earlier work indicated correlation of serum CSF-1 with breast cancer staging, and a recent report suggests that CSF-1 is a potential breast cancer marker, however the data reported so far await validation.
  • METHODS: In a prospective study in 799 women with no history of malignant disease undergoing surgery, serum CSF-1 levels were measured by a commercially available ELISA.
  • In this cohort, 312 patients had breast cancer and 487 age-matched women had benign tumors.
  • The tumor size, nodal and metastasis status, histological tumor type, hormone and human epidermal growth factor receptor 2 (HER2) and menopausal status were evaluated.
  • Mean CSF-1 serum concentrations were compared between the patient groups by non-parametric Wilcoxon two-sample and Kruskal-Wallis test.
  • RESULTS: Mean serum CSF-1 concentrations were significantly higher in all patients with malignant tumors (502±429 pg/mL) as compared to those with benign tumors (382±344 pg/mL) (p<0.0001, Wilcoxon).
  • Increased CSF-1 concentrations were significantly related to malignant versus non-malignant disease in logistic regression and receiver operating characteristic analysis (p<0.0001, AUC=0.6).
  • Increased CSF-1 levels in patients with malignant tumors were associated with postmenopausal (p=0.0038) but not premenopausal (p=0.94) status (Wilcoxon).
  • Serum CSF-1 concentrations did not correlate significantly with tumor size, nodal and metastasis status, hormone receptor and HER2 status of patients (Kruskal-Wallis).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963190.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Spensley S, Gilmore JA, Kenny J, Dunne M, Clayton-Lea A, Thirion PG: Functional outcome of malignant spinal cord compression treated with radiotherapy alone: A prospective analysis. J Clin Oncol; 2009 May 20;27(15_suppl):e20623

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Functional outcome of malignant spinal cord compression treated with radiotherapy alone: A prospective analysis.
  • : e20623 Background: Malignant spinal cord compression (MSCC) is a major oncological complication.
  • The management of Impending Malignant Spinal Cord Compression (IMSCC) remains unclear.
  • Non-eligible pts were prospectively evaluated and followed with assessment of mobility (modified Tomita scale) and sphincter function (continence/ incontinence/catheter) at baseline and 5 weeks posttreatment.
  • The primary tumours were haematological [13 pts], lung [10], prostate [8], renal cell [6] and breast [5].
  • New sphincter dysfunction after RT was seen in 2 pts with IMSCC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961600.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Wagner LM, Perentesis JP, Reid JM, Ames MM, Safgren SL, Nelson MD, Ingle AM, Blaney SM, Adamson PC: Phase I trial and pharmacokinetic study of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with refractory solid tumors: A Children's Oncology Group Phase I Consortium study. J Clin Oncol; 2009 May 20;27(15_suppl):10017

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial and pharmacokinetic study of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with refractory solid tumors: A Children's Oncology Group Phase I Consortium study.
  • We sought to determine the dose limiting toxicities (DLTs) and maximum tolerated dose (MTD) of orally administered IRN given on two different schedules together with TMZ and VCR in children with refractory solid tumors, using cefixime to reduce IRN-associated diarrhea.
  • First-course and cumulative toxicity appeared worse with Schedule A, including 3 patients with responding or stable tumors who withdrew due to fatigue, nausea, and weight loss.
  • At the oral IRN MTD of 90 mg/m<sup>2</sup>/d, the median SN-38 AUC<sub>inf</sub> was 72 ng/ml*h.
  • Eight additional patients received > 6 courses, including 2 each with neuroblastoma and medulloblastoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962502.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Lorch A, Beyer J, Mollevi C, Guerra M, Kramar A, International Group on Prognostic Factors in Relapsed or Refractory Germ-Cell Tumors: Prognostic factors in relapsed or refractory male germ cell tumors: Results from an international study of 1,593 patients. J Clin Oncol; 2009 May 20;27(15_suppl):5030

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in relapsed or refractory male germ cell tumors: Results from an international study of 1,593 patients.
  • : 5030 Background: The results of salvage treatment in male patients (pts) with relapsed or refractory germ-cell tumors (rr-GCT) depend considerably on prognostic factors.
  • Cisplatin-refractory or absolute refractory disease was a confounding factor for response to first-line treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962922.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Morice P, Uzan C, Kane A, Rey A, Gouy S, Pautier P, Camatte S, Lhomme C, Haie-Meder C, Duvillard P: Prognostic factors of patients with advanced stage serous borderline tumors of the ovary. J Clin Oncol; 2009 May 20;27(15_suppl):5573

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors of patients with advanced stage serous borderline tumors of the ovary.
  • : 5573 Background: The aim of this study was to determine prognostic factors in a large series of patients with stage II or III serous low malignant potential ovarian tumor (LMPOT) and peritoneal implants.
  • The slides of ovarian tumors and peritoneal implants were reviewed by the same pathologist.
  • Tumors exhibited a micropapillary pattern in 56 patients.
  • Among patients with noninvasive and invasive implants, 8% and 10%, respectively, relapsed at 5 years in the form of invasive disease (p = 0.08).
  • The strongest prognostic factor in patients with an advanced-stage borderline tumor is the use of conservative surgery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962609.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Choi Y, Song M, Seol Y, Kwon B, Shin H, Chung J, Lee J, Lee B, Kim S, Sohn C, Cho G: Use of tumor volume as measured on F18FDG-PET/CT scan as a predictive biomarker for head and neck cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e17019

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of tumor volume as measured on F18FDG-PET/CT scan as a predictive biomarker for head and neck cancer.
  • : e17019 Background: Functional imaging, PET and its fusion with anatomical modalities, PET/CT promise to improve detection and characteristic disease.
  • The objective of this study was to evaluate metabolic tumor volume as measured on F-18 FDG-PET/CT and its association with treatment response and prognosis in patients with head and neck cancer.
  • Before treatment patients were taken FDG-PET/CT scan, SUVmax, tumor volume, metastasis were recorded.
  • The mean tumor volume was 21.3 cm<sup>3</sup> (range, 0.2-170).
  • There was no correlation between tumor volume and SUVmax (correlation coefficient 0.295).
  • But higher tumor volume was associated with an increased risk of lymph node and distant metastasis at diagnosis (p = 0.063).
  • The metabolic tumor volume as measured on PET/CT scans was predictor of treatment response and disease -free survival.
  • The disease free survival were 31.1month for an SUVmax <5.5, 4.6months for an SUVmax > 5.5 (p = 0.025).
  • CONCLUSIONS: The metabolic tumor volume as measured on F-18FDG-PET/CT is a predictive biomarker of treatment response and disease free survival for patients with head and neck cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961710.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Burg ME, Janssen JT, Ottevanger PB, Kerkhofs LG, Valster F, Stouthard JM, Onstenk W, Termorshuizen F, Verweij J: Multicenter randomized phase III trial of 3-weekly paclitaxel/platinum (PC3w) versus weekly paclitaxel/platinum (PCw) induction therapy followed by PC3w maintenance therapy in advanced epithelial ovarian cancer (EOC). J Clin Oncol; 2009 May 20;27(15_suppl):5538

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: 270 patients (pts) with FIGO stage II-IV, Performance status (PS) 0-2 were randomly assigned to 3 x PC3w (P 175mg/m2 with either cisplatin [Cis] 75mg/m<sup>2</sup> or carboplatin [Car] AUC 6) or 6 x PCw (P 90mg/m2 with either Cis 70mg/m<sup>2</sup> or Car AUC 4, day 1,8,15 and day 29,36,43) followed by up to 6 cycles PC3w in both arms.
  • Pts were stratified for FIGO stage, PS, tumor size and center.
  • RESULTS: 267 pts (134 TC-3w and 133 TCw) were eligible (3 pts wrong tumor type).
  • Pt characteristics were well balanced; median age 58 years, serous 62%, residual disease >1cm 66%, FIGO stage II 7%, III 64%, IV 29%.
  • Median dose-intensity for PC3w was: P 58(47-58) and Cis 25(22.5-25) mg/m<sup>2</sup>/w, Car 2(1.6-2) AUC/w, for PCw: P 60(36-60) and Cis 44.7(30-44.7) mg/m<sup>2</sup>/w and for Car 2.7(1,6-2,7) AUC/w.
  • RR after induction therapy in 176 pts with measurable disease was 72% for TC3w and 74% for TCw (p = 0.68).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962486.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Parker S, Berman D, Bennett KL, Alaparthy S, Tsuchihashi Z, Chasalow SD, Zhan P: Increased humoral and cellular immunity in patients (pts) with advanced melanoma treated with ipilimumab. J Clin Oncol; 2009 May 20;27(15_suppl):3031

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Humoral response to 5 tumor antigens (Ag) and a control Ag (DHFR) were examined at baseline (BL) and at Wks 4, 8-9, and 12.
  • Peripheral T-cell populations were evaluated through flow cytometry at BL, Wk 4, and Wk 12.
  • Increases from BL in humoral responses to pneumococcal (40-50/78 pts, depending on Ab) and tetanus (58/78 pts) vaccines were noted, even in pts who did not receive on-study pneumococcal (4-9 pts) or tetanus (7 pts) vaccines.
  • Maximum increase from BL of ≥ 5-fold titer (clinically meaningful threshold) in humoral response to tumor Ag MELANA (23.2% of pts), SSX2 (20.3%), NYES01 (18.8%), MAGEA4 (10.1%), and P53 (4.3%) (DHFR, 4.3%) was noted without tumor vaccines.
  • Tumor Ag response was not associated with clinical activity (complete or partial response, or stable disease ≥ 24 wks).
  • Significant increases from BL in percents of HLA-DR+ CD4+ (p = 9.3x10<sup>-7</sup>), HLA-DR+ CD8+ (p = 0.018), and ICOS+ CD4+ (p = 0.0027) effector T cells were noted.
  • Change in tumor Ag response was not associated with clinical activity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962083.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Sausville E, Garbo L, Weiss GJ, Anthony S, Shkolny D, Yurkovetskiy AV, Bethune C, Fram RJ: A phase I study of the safety and pharmacokinetics (PK) of XMT-1001 given as an intravenous (IV) infusion once every three weeks to patients with advanced solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):2574

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study of the safety and pharmacokinetics (PK) of XMT-1001 given as an intravenous (IV) infusion once every three weeks to patients with advanced solid tumors.
  • XMT-1001 demonstrated an improved therapeutic window as compared with CPT and irinotecan in human tumor xenograft models, providing a compelling rationale for its clinical development.
  • RESULTS: Thirty two pts with refractory solid tumors have received 82 cycles of XMT-1001 at 8 dose levels ranging from 1.0 to 20.5 mg CPT equivalents/m<sup>2</sup>.
  • After the introduction of new clinical trial material with an improved formulation, to date, no infusion reactions suggestive of hypersensitivity have occurred (11 patients, 22 cycles).
  • Stable disease was observed in 7 pts with the following tumor types and dose levels expressed in mg CPT equivalents/m<sup>2</sup>: NSCLC (1.0 mg/m<sup>2</sup>, 6 wks), ovarian (4.9 mg/m<sup>2</sup>, 12 wks), pancreas (4.9 mg/m<sup>2</sup>, 36 wks), appendiceal (7.3 mg/m<sup>2</sup>, 12 wks), bile duct (9.1 mg/m<sup>2</sup>, 18 wks), basal cell (11.6 mg/m<sup>2</sup>, 6 wks), and colon (15.4 mg/m<sup>2</sup>, 6 wks).
  • Prolonged stable disease was observed in patients with refractory tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961894.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Carroll PA, Healy L, Lysaght J, Griffin M, Dunne B, Boyle MT, Reynolds JV, Kennedy MJ, Pidgeon G, Connolly EM: Mammary adipose tissue and cancer cell growth: The role of adipose tissue in the tumor microenvironment. J Clin Oncol; 2009 May 20;27(15_suppl):e22009

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mammary adipose tissue and cancer cell growth: The role of adipose tissue in the tumor microenvironment.
  • Adipose tissue is considered an important endocrine organ producing several important hormones and cytokines including leptin and adiponectin.
  • Mechanisms for the role of obesity in cancer states includes the excess or unregulated secretion of adipocytokines from adipose tissue, and potentially the metabolic syndrome (a cluster of co-morbidities linked to metabolic dysregulation).
  • Mammary adipose tissue is proposed to play a vital role in the microenvironment of normal and tumour states within the breast<sup>2</sup>.
  • METHODS: Peritumoural (PT) adipose tissue adjacent to the tumour and distal adipose tissue (D) within the breast was sampled in 10 patients.
  • RESULTS: ACM from both sites promoted tumour cell survival.
  • This may be mediated through increased pro-inflammatory or pro- mitogenic adipocytokine production in adipose tissue surrounding tumour.
  • Further analysis will determine what role obesity and the metabolic syndrome plays in the results noted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963182.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Erbersdobler A, Simon R, Hellwinkel OJ, Bokemeyer C, Sauter G, Hu-Lowe D, Levin W, Gallo-Stampino C, Fiedler W: Analysis of expression of TGF-β1 receptor (ALK-1) in normal and tumor tissues by tissue microarrays. J Clin Oncol; 2009 May 20;27(15_suppl):e22044

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of expression of TGF-β1 receptor (ALK-1) in normal and tumor tissues by tissue microarrays.
  • Here we describe target validation in normal and tumor tissue using tissue micro-arrays (TMAs).
  • Multi-tumor arrays consisted of 3923 individual tumor samples from 87 tumor types.
  • RESULTS: ALK-1 staining of vessels in normal tissues was generally weak (mostly grade 1 and rarely grade 2) and was detectable in lymphatic tissues including tonsil, lymph nodes, thymus and spleen, lung, the entire GI tract including parotid, submandibular and sublingual glands as well as pancreas.
  • ALK-1 positive vessels were also found within the female genital tract including placenta, uterus and ovary.
  • In human tumor vessels ALK-1 expression showed high variability between tumor types.
  • The highest ALK-1 expression rate was found in lung cancer (NSCLC 49%, SCLC 83%), neuroendocrine pancreas tumor (71%), colon cancer (50%), chondrosarcoma 50%, angiosarcoma 40% and NHL (44%).
  • CONCLUSIONS: TMAs are an excellent tool to verify target expression in normal and tumor tissues.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963226.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Macdonald JS, Benedetti J, Smalley S, Haller D, Hundahl S, Jessup J, Ajani J, Gunderson L, Goldman B, Martenson J: Chemoradiation of resected gastric cancer: A 10-year follow-up of the phase III trial INT0116 (SWOG 9008). J Clin Oncol; 2009 May 20;27(15_suppl):4515

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Initial results (NEJM 345: 725, 2001) showed both overall and disease free survivals improved by chemoradiation.
  • RESULTS: INT0116 continues to show benefit for chemoradiation with hazard ratios (HR) for survival (HR=1.32, p=.004) and disease free survival (HR=1.51, p<.001) favoring chemoradiation.
  • Subset analyses were performed for sex, race, T and N stage, D-level of surgical resection, tumor location (proximal or other), histology (intestinal or diffuse) and Maruyama index.
  • Thirty-five second tumors occurred in 31 cases.
  • Second tumors represented a spectrum of types of neoplasms commonly occurring in this age group (median age 60 years).
  • Excessive numbers of tumors known to be caused by radiation and/or chemotherapy were not noted.
  • More tumors may have occurred in the treated patients since their death rates were less than surgery only cases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962700.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Tamura N, Tamura N: Prognostic factors for patients with invasive ductal carcinoma of the breast who received neoadjuvant chemotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):e11617

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The multivariate analyses with an assessment of pathological effect of NAC, grading system for lymph vessel tumor emboli (LVTE), and histological factors of tumors in lymph nodes in addition to well-known prognostic clinicopathological factors were performed in IDC patients with nodal metastasis and in those of pTNM stage III as well as IDC patients as a whole.
  • Severe tumor stroma in nodal metastatic tumors significantly increased the HRs of tumor recurrence of IDC patients in the both group.
  • Number of mitotic figures in nodal metastatic tumors significantly increased the HRs of tumor death in IDC patients with nodal metastasis.
  • Tumor necrosis in primary-invasive-tumors was a significant factor for tumor recurrence of patients in the both.
  • CONCLUSIONS: The study clearly demonstrated that grading system for LVTE, and characteristics of nodal metastatic tumors as well as the presence of tumor necrosis in primary-invasive tumors are very important prognostic factors for IDC patients who received NAC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961152.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Poultsides GA, Servais EL, Saltz LB, Patil S, Kemeny NE, Guillem JG, Weiser M, Temple LK, Wong W, Paty PB: Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol; 2009 May 20;27(15_suppl):CRA4030

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment.
  • : CRA4030 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961295.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Anthoney DA, MacPherson I, Twelves C, Crawford D, Siller C, Nemat S, Abe M, Miwa M, Evans J: Phase I study of TP300 in patients (pts) with advanced solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):2563

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of TP300 in patients (pts) with advanced solid tumors.
  • METHODS: Eligible pts with refractory, advanced solid tumors who had adequate PS, hematologic, renal, and hepatic function were recruited into this open-label, modified- Fibonacci dose escalation ("3 + 3" pts/dose level, with expansion at the MTD) study.
  • Seven pts, all previously treated with irinotecan, had disease stabilisation for 1.5-5 months.
  • CH0793076 PK (AUC and C<sub>max</sub>) were linear from 1 to 10mg/m<sup>2</sup>.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961884.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Cioffi A, LeCesne A, Blay J, Delaloge S, Yovine A, Maki R, Nieto A, Jiao JJ, Demetri GD: Trabectedin phase II clinical trials: Pooled analysis of safety in patients with solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e13510

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trabectedin phase II clinical trials: Pooled analysis of safety in patients with solid tumors.
  • This retrospective report on safety includes single-agent trabectedin phase II studies in patients (pts) with solid tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961298.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Weidner S, Schilling MB, Parks C: Costs and outcomes associated with hospitalizations for venous thromboembolic disease in patients with malignant neoplasm. J Clin Oncol; 2009 May 20;27(15_suppl):6590

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Costs and outcomes associated with hospitalizations for venous thromboembolic disease in patients with malignant neoplasm.
  • : 6590 Background: Venous thromboembolic disease (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE) is a common occurrence in oncology, as patients with cancer have a greatly increased risk of VTE.
  • Costs of VTE treatment are significant, including direct costs (expenditures for procedures, tests, medications, and services), indirect morbidity costs (lost income from work due to the condition or disability), and indirect mortality costs (lost income due to early mortality).
  • Costs associated with VTE contribute to the overall cost of cancer care, however studies that examine the cost of care for oncology patients that develop VTEs are limited.
  • Patients with an ICD-9-CM code for malignant neoplasm (140.xx-208.xx) in combination with DVT or PE (415.11,415.19, 453.4,453.41,453.42) were included.
  • Overall 1136 inpatients were identified with a diagnosis of malignant neoplasm and either DVT or PE.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963853.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Devitt P, Breathnach O, Grogan L, Cotter D, MacHale S: Rates of psychiatric illness in patients with cancer: An analysis of a psycho-oncology service. J Clin Oncol; 2009 May 20;27(15_suppl):e20731

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rates of psychiatric illness in patients with cancer: An analysis of a psycho-oncology service.
  • Psycho-oncology services are limited throughout the country.
  • METHODS: Case notes from all patients referred by medical oncologists, clinical nurse specialists and/or social workers to the psycho-oncology service were reviewed for the period 7/07 to 6/08.
  • More patients were referred with localised disease in 07/08 than in 2003 (37.5% vs .19%, p=0.012).Patients with a past history of psychiatric disorder were more likely to be referred in 07/08 compared to 2003 (54% vs. 32% p=0.005).
  • There was a significant decrease in the numbers diagnosed with depression in 07/08 (29% vs. 51%, p= 0.004) with a corresponding increase in the diagnosis of adjustment disorder (26% vs. 6%).
  • CONCLUSIONS: Psycho-oncology services remain an important component of care for patients with cancer.
  • The increased rate of referrals may reflect an increased awareness amongst oncology staff of psychological distress in this vulnerable population.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962010.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Recht LD, Mechtler L, Phuphanich S, Hormigo A, Hines V, Milsted R, O'Connor PC, Ryan RP, Wong ET: A placebo-controlled study investigating the dexamethasone-sparing effects of corticorelin acetate in patients with primary or metastatic brain tumors and peritumoral edema. J Clin Oncol; 2009 May 20;27(15_suppl):2078

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A placebo-controlled study investigating the dexamethasone-sparing effects of corticorelin acetate in patients with primary or metastatic brain tumors and peritumoral edema.
  • : 2078 Background: The standard therapy for patients with peritumoral edema (PTE) associated with cerebral tumors is long-term dexamethasone (dex), which is associated with significant short- and long-term adverse events (AEs).
  • This study investigated the steroid-sparing effect of CrA in patients with cerebral tumors and PTE.
  • CONCLUSIONS: CrA may benefit patients with symptoms of PTE associated with primary or metastatic cerebral tumors by allowing them to reduce/stop their dex treatment, so reducing the incidence of the steroid-related AEs of myopathy, cushingoid symptoms, and skin disorders.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964375.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Bumcrot D, Toudjarska I, Judge A, Brodsky J, Ambegia E, Buck T, Racie T, Jeffs L, MacLachlan I, Gollob J, Sah DW: Advancement to the clinic of an RNAi therapeutic for solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):3585

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advancement to the clinic of an RNAi therapeutic for solid tumors.
  • : 3585 Background: Malignancies of the liver, including primary (hepatocellular carcinoma) and secondary (metastatic) tumors, represent a significant unmet medical need.
  • We are developing a therapeutic for solid tumors involving the liver that is comprised of lipid particle-formulated short interfering RNAs (siRNAs) targeting VEGF and the mitotic kinesin, KSP (Eg5).
  • Efficacy was demonstrated in a mouse liver tumor model.
  • A SNALP-formulated combination of the KSP and VEGF siRNAs (referred to as ALN-VSP01) was tested in an orthotopic liver tumor model in which human hepatoma cells (Hep3B) are implanted directly into the livers of immunocompromised mice.
  • RESULTS: Intravenous administration of ALN-VSP01 leads to dose-dependent inhibition of both KSP and VEGF expression in established liver tumors.
  • This was accompanied by the formation of numerous aberrant mitotic figures ("monoasters") in tumor cells indicative of the pharmacologic inhibition of KSP.
  • In addition, tumor growth was significantly inhibited by a course of ALN-VSP01 treatment, and ALN-VSP01 treatment provided a clear survival benefit even when treatment was initiated in animals with a significant tumor burden.
  • CONCLUSIONS: Systemic administration of ALN-VSP01 exhibited clear efficacy in a mouse orthotopic liver tumor model.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961752.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Eisterer WM, De Vries A, Oefner D, Greil R, Rabl H, Tschmelitsch J, Schmid R, Kapp K, Zehentmayr F, Thaler J: Neoadjuvant chemoradiation therapy with capecitabine (X) plus cetuximab (C), and external beam radiotherapy (RT) in locally advanced rectal cancer (LARC): ABCSG trial R03. J Clin Oncol; 2009 May 20;27(15_suppl):4109

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • X and C are synergistic with radiotherapy and active in colorectal neoplasms.
  • Only patients (pts.) with MRT-documented T3/T4-tumours were included.
  • 21 pts. (68%) presented with cT4, 10 pts. (32%) with cT3 tumors.
  • Treatment with X and C plus RT was well tolerated, in only 4 pts. grade 3 toxicity was observed: acneiform skin rash 2 pts (7%), diarrhea 3 pts (11%), 1 pt. (4%) suffered from grade 4 diarrhea.
  • Median dose intensity of X and C was >95% during the entire treatment period.
  • Tumor downstaging was observed in 14 pts. (50%) total, 12/19 (63%) T4 tumours and 2/9 (22%) T3 tumors responded.
  • The combination is effective in the primary tumor as well as in the lymph nodes, both with possible impact on therapy outcome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961175.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Perazzo F, Denninghoff V, Pasccon G, Pallotta MG, Tatangelo M, Cuartero V, Kirchuck R, Chacón M, Gennari L, Vera K, Avagnina A: Preliminary report of the mutation status of KRAS and BRAF-V600E in an Argentinean population of primary colorectal tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e22183

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary report of the mutation status of KRAS and BRAF-V600E in an Argentinean population of primary colorectal tumors.
  • The aim of this report is to present the mutational status of KRAS, BRAF and epidemiological data of an Argentinean population of CR tumors which may have future clinical practice implications.
  • 41.4% (60) have family history of cancer and 9.6% (14) have personal history of a previous tumor.
  • The primary tumor site was 21.9% (32) right colon, 5.5% (8) transverse colon, 45.2% (66) left colon and 27.4%(40) rectal cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963599.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Ide S, Motwani M, Jensen MR, Wang J, Huseinovic N, Stiegler P, Wang X, Quadt C: Pharmacodynamics and pharmacokinetics of AUY922 in a phase I study of solid tumor patients. J Clin Oncol; 2009 May 20;27(15_suppl):3533

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacodynamics and pharmacokinetics of AUY922 in a phase I study of solid tumor patients.
  • We evaluated HSP70 as a pharmacodynamic (PD) marker of AUY922 activity in a phase I/II clinical trial in patients (pts) with solid tumors.
  • Baseline levels of HSP70 in PBMC ranged from 26.0 to 95.1 ng/mg protein, with a median of 42.5ng/mg.
  • The degree of HSP70 upregulation in PBMCs at 40 mg/m<sup>2</sup> exceeds the 8-fold upregulation seen in BT474 xenograft tumor tissue when treated with efficacious doses of AUY922.
  • Additionally, our analysis suggests that in humans, the PD effect of AUY922 is reaching the level corresponding to that required for anti-tumor effect in the BT474 xenograft model.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961339.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Robert F, Verschraegen C, Hurwitz H, Uronis H, Advani R, Chen A, Taverna P, Wollman M, Fox J, Michelson G: A phase I trial of sns-314, a novel and selective pan-aurora kinase inhibitor, in advanced solid tumor patients. J Clin Oncol; 2009 May 20;27(15_suppl):2536

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I trial of sns-314, a novel and selective pan-aurora kinase inhibitor, in advanced solid tumor patients.
  • : 2536 Background: Aurora Kinases are a family of serine/threonine kinases (Aurora Kinases (AK) A, B, and C) critical for mitosis.
  • Elevated AKs expression occurs in a high percentage of melanoma, colon, breast, ovarian, gastric, and pancreatic tumors; in a subset of these tumors the AURKA locus (20q13) is amplified.
  • Patients (pts) with advanced solid tumors received SNS-314 by 3 hour infusion qweek X 3 (28 day cycle).
  • Six patients had stable disease as their best response.
  • CONCLUSIONS: SNS-314 is a novel inhibitor of AKs A, B, and C.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961850.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Choueiri TK, Regan M, Oh W, Clement J, Amato A, McDermott D, Cho D, Atkins M, Signoretti S: Prognostic and predictive values of carbonic anhydrase IX (CAIX) and pathologic features in patients with metastatic clear cell renal cell carcinoma receiving targeted therapy. J Clin Oncol; 2009 May 20;27(15_suppl):e16067

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e16067 Background: Tumor Carbonic Anhydrase IX (CAIX) expression and histologic features can predict outcome in patients with metastatic renal cell carcinoma (mRCC) treated with immunotherapy.
  • METHODS: We identified 118 patients with mRCC initiating first- line VEGF-targeted therapy including 94 with clinical data, clear cell histology and available tissue.
  • Tumors were evaluated for specific histologic features and for CAIX expression by immunohistochemistry using the MN75 antibody.
  • The relationship between these pathology findings and tumor shrinkage and other treatment outcomes was assessed.
  • RESULTS: Higher tumor clear cell component was independently associated with greater tumor shrinkage (p=0.02), response (p=0.02) and treatment duration (p=0.02).
  • Patients with high vs. low tumor CAIX expression had mean tumor shrinkages of -12% vs. -5%, respectively (p=.38).
  • There was heterogeneity in tumor responsiveness to sunitinib or sorafenib according to CAIX status (p=0.055 for interaction): mean shrinkage was -17% vs. -25% (mean difference +8%, 95% CI -14% to +31%) for sunitinib-treated patients with high vs. low tumor CAIX expression compared to -13% vs. +9% (mean difference -22%, 95% CI -42% to -1%) for sorafenib-treated patients.
  • CONCLUSIONS: Patients with higher clear cell component in their tumors are likely to experience superior clinical benefit from VEGF-targeted therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963063.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Heinrich MC, Carden R, Griffith D, Liang C, Marino-Enriquez A, McKinley A, Presnell A, Fletcher JA: In vitro activity of sorafenib against imatinib- and sunitinib-resistant kinase mutations associated with drug-resistant GI stromal tumors. J Clin Oncol; 2009 May 20;27(15_suppl):10500

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro activity of sorafenib against imatinib- and sunitinib-resistant kinase mutations associated with drug-resistant GI stromal tumors.
  • : 10500 Background: Most gastrointestinal stromal tumors (GISTs) harbor mutant KIT or platelet-derived growth factor receptor alpha (PDGFRA) kinases, which are targets of imatinib (front-line therapy) or sunitinib (second-line therapy).
  • We also tested the biochemical and cellular activity of SOR and IM against GIST cells derived from IM-resistant tumor clones.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963686.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Littlejohn JE, Jupiter D, Cao X, Zhang L, Shabahang M, Smythe WR: BNIP3L (Nix) expression in colon cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15097

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e15097 Background: Microenvironmental adaptation to hypoxic conditions is critical for a cell to survive in a growing solid tumor.
  • BNIP3L (Nix) mediates apoptosis during hypoxia in cancer cell lines, and Nix knockdown promotes tumor growth in-vivo through decreased apoptosis and increased proliferation, suggesting a means by which cells can adapt.
  • To gain insight into expression of this gene in colon tumors, the present study analyzed mRNA microarray data from 227 colon tumors and 22 normal colon tissue samples and queried differential expression of Nix.
  • These results were compared to the protein levels present in human colon tumors.
  • METHODS: mRNA expression of 227 human colon tumors (made available by the Expression Project for Oncology (expO)) and 22 normal colon samples (retrieved from the Gene Expression Omnibus (GEO)) was analyzed.
  • Immunohistochemistry was performed on human tissue microarray CO701 (US Biomax, Inc.) containing 62 tumor samples.
  • IHC demonstrated variable levels of Nix present in colon tumors: 38/62 (61.3%) of tumors stained positive for Nix while 24/62 (38.7%) were negative.
  • CONCLUSIONS: We have shown that mRNA levels of Nix are upregulated in the transition from normal colon tissue to cancer but that protein levels in tumors demonstrate variable expression.
  • This suggests that silencing of Nix occurs at various stages of tumorigenic progression and results in isolated populations of cells within a growing tumor that are uniquely resistant to apoptosis.
  • Better understanding of Nix in the context of a growing colon tumor is needed and could lead to development of more successful therapeutics.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964610.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Nishida T, Takahashi T, Nakajima K, Tsujinaka T, Hirota S: KIT and PDGFRA mutations of gastrointestinal stromal tumor. J Clin Oncol; 2009 May 20;27(15_suppl):10560

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KIT and PDGFRA mutations of gastrointestinal stromal tumor.
  • : 10560 Background: KIT or PDGFRA mutations are found in gastrointestinal stromal tumors (GIST) and are correlated with imatinib (IM) effects.
  • Here we examined full sequence of the genes using frozen section of GI mesenchymal tumors.
  • Using RNA obtained from fresh samples of serial 209 pts with GIST (n=174), myogenic (21), neurogenic tumors (11), or GI sarcoma (3), KIT or PDGFRA cDNA was amplified by RT-PCR and fully sequenced.
  • RESULTS: Tumors other than GIST showed no KIT-immunoreactivity, and had no-PCR-products of KIT (32) or wild type (WT) (3).
  • PDGFRA of these tumors is WT.
  • Ex 13 and 17 mutations are missense and Ex 11 showed various type of mutations including deletion, insertion and missense mutations.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963809.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Bellizzi AM, Bloomston M, Bellizzi SM, Marsh WL, Frankel WL: Assessment of prognostic factors in pancreatic ductal adenocarcinoma: Focus on the retroperitoneal margin. J Clin Oncol; 2009 May 20;27(15_suppl):e15670

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumors were assessed for the following: size, stage, grade, lymph node (LN) status, vascular and perineural invasion, and margin status.
  • Margin status was evaluated in 3 ways: traditional margins (tumor at pancreatic neck, bile duct, and/or uncinate margins), 1 mm margins (traditional + tumor within 1 mm of UM), and PPS margins (traditional + tumor within 1 mm of PPS or UM).
  • RESULTS: Fifty-one tumors exhibited the following features: size (mean 3.3 cm), stage (48 T3), grade (27 low, 24 high), LN status (11 neg, 40 pos), positive margins (13 traditional, 23 1 mm, and 32 PPS).
  • Nearly all tumors exhibited at least focal vascular and perineural invasion.
  • Neither tumor size, LN status, nor traditional or PPS margins are significant, while 1 mm margins trend toward significance.
  • Additional study of 1 mm margins in a larger tumor set is warranted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962842.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement